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1. INTRODUCTION 
Normal hemostasis is  not only a complex but also an ingenious 
system which maintains blood in the vascular system free from clots,the 
vital element of the process being the platelet1.Decreased platelet count is 
not as common as anemia,the hematological cousin. Literature quotes the 
incidence of thrombocytopenia to vary from 13 to 58% in various 
studies2.But it is far more dangerous and resource consuming to the 
emergency department and the ICU setting.It can be associated with 
bleeding ranging from minor bleeds to life threatening intracranial 
hemorrhage. 
There is very often a poor correlation between the extent of 
thrombocytopenia and the severity of the bleed.Guidelines on platelet 
transfusions are also varied and  confounding.Hence the treatment of 
thrombocytopenia has to be guided by an understanding of the cause and 
clinical course.It is often said that the main treatment goal in all patients 
with decreased  platelet count is to maintain a safe platelet level so as to 
prevent significant bleeding.But what constitutes a safe count in a specific 
patient varies, depending on the etiology of the thrombocytopenia as 
regards to whether it is transient or  chronic, as well as the patient’s 
expected level of disease activity3. 
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There have been a plethora of studies on anemia and its impact on 
various disease processes.But thrombocytopenia is still a grey area waiting 
to be explored.Again,there are lot of studies in the adult population 
detailing the outcome of patients with thrombocytopenia in the Intensive 
care  setting4.But similar studies in the paediatric age group are lacking. No 
particular study has been addressed towards studying the relative frequency 
of different disease conditions presenting as newly diagnosed 
thrombocytopenia in paediatric patients presenting to an Indian tertiary care 
hospital. The need arises to look at thrombocytopenia as a whole and to 
gather knowledge regarding the common disease entities  presenting as 
thrombocytopenia, the clinical course in the  hospital of patients presenting 
as such and whether or not active treatment modalities like platelet 
transfusions, steroids, platelets are required in them. This knowledge will 
give the clinician an idea of approach to a paediatric patient detected to 
have thrombocytopenia on admission to a tertiary care hospital in India.  
The present study was thus undertaken to evaluate the occurrence of 
thrombocytopenia,assess the cause for it  and the associated mortality and 
morbidity in paediatric  patients. In addition,the association with bleeding 
and the requirement of blood products was also studied. 
 
 
 
  
 
11 
 
 
 
 
AIMS AND OBJECTIVES 
 
 
 
 
 
 
 
 
 
  
 
12 
 
2. AIMS AND OBJECTIVES 
AIMS OF THE STUDY: 
To assess the clinical and laboratory profile of patients having 
thrombocytopenia(<1 lakh) admitted as inpatients in the children medical 
ward of Tirunelveli Medical College Hospital. 
OBJECTIVES OF THE STUDY: 
1. To evaluate the relative frequency of different disease conditions 
presenting as newly found thrombocytopenia and to identify the cause 
for thrombocytopenia in children. 
2. To assess the clinical complications,outcome and prognosis associated 
with thrombocytopenia,especially the proportion of patients who had 
bleeding manifestations. 
3. To evaluate the percentage of patients requiring interventions like 
platelet substitutes, steroids,other blood products and to determine 
whether a low platelet count or presence of bleeding manifestations was 
considered as an  indication for platelet transfusions. 
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3.  REVIEW OF LITERATURE 
HISTORY OF THROMBOCYTES : 
In 1877, Osler coined the term thrombocytes or haematoblasts of 
Deetjen and Dekhuyzen (1901) and elucidated the role of these third 
corpuscles as fibrin formers in coagulation. 
PLATELETS-BRIEF NOTE ON ROLE IN NORMAL PHYSIOLOGY: 
Platelets play a central role in normal hemostasis and therefore also 
in thrombosis. Despite their lack of nucleus, they (about 2 micrometer in 
diameter) are amazingly versatile. In the haemostatic cascade platelets 
undergo 3 important reactions: (1) adhesion and shape change, (2) secretion 
and (3) aggregation, collectively called to as platelet activation5.The 
platelet surface has a number of  receptors for adhesive proteins, including 
von Willebrand factor (VWF) and fibrinogen, as well as receptors for 
platelet aggregation,like thrombin, collagen and adenosine diphosphate 
(ADP). After injury to the vessel wall, subendothelial collagen binds VWF. 
VWF undergoes a conformational change that induces binding of the GPIb 
complex (the VWF receptor). This is called platelet adhesion. Platelets then 
undergo activation. During activation, the platelets generate thromboxane 
A2 from arachidonic acid via cyclo-oxygenase.After activation,agonists 
such as ADP, ATP, Ca2+, serotonin, and coagulation factors,are released 
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into the surrounding milieu. Circulating fibrinogen binds to the GPIIb-IIIa 
complex, linking platelets together.This process is called aggregation. 
These events lead to the development of a hemostatic plug at the site 
of vascular injury. The serotonin and histamine that are released during 
activation increase the local vasoconstriction. In addition to these actions, 
the platelet also provides the catalytic surface on which clotting factors 
assemble and eventually generate thrombin.Lastly, the platelet contractile 
proteins and cytoskeleton play a role in clot retraction6. 
DEFINITION OF THROMBOCYTOPENIA: 
There are an  estimated 15,000,000 megakaryocytes/kg body weight 
in the body,each of which produces approximately 1000–1500 
platelets7.Normal platelet count ranges between 1.5 lakhs to 4.0 lakhs per 
microlitre.Definition of thrombocytopenia is not unequivocal as some 
books8  indicate it  as less than 100×109/L and  others as less than 
150×109/L; but a working definition of less than 1 lakh is widely 
accepted.Furthermore, it is considered mild (and usually asymptomatic)if 
above 50×109/L, moderate if it is between 30×109/L and 50×109/L,and 
severe if the platelet count is below 30×109/L.9  
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FIGURE 1: ELECTRON MICROSCOPIC IMAGE OF                                                                                                                                                  
THE PLATELET 
 
 
FIGURE 2:PETECHIAE AND PURPURA 
ETIOLOGY: 
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The causes of thrombocytopenia include:  
1. DECREASED PRODUCTION on either a congenital or an acquired basis;  
2. SEQUESTRATION of the platelets within an enlarged spleen or other 
organ; and  
3. INCREASED DESTRUCTION of normally synthesized platelets on either 
an immune or a nonimmune basis. 
TABLE 1:DIFFERENTIAL DIAGNOSIS OF THROMBOCYTOPENIA IN 
CHILDREN AND ADOLESCENTS:10 
DESTRUCTIVE THROMBOCYTOPENIAS 
    Primary Platelet Consumption Syndromes 
     Immune thrombocytopenias 
      Acute and chronic ITP(Idiopathic thrombocytopenic purpura) 
      Autoimmune diseases with chronic ITP as a manifestation 
       Cyclic thrombocytopenia 
       Autoimmune lymphoproliferative syndrome and its variants 
       Systemic lupus erythematosus 
       Evans syndrome 
       Antiphospholipid antibody syndrome 
       Neoplasia-associated immune thrombocytopenia 
      Thrombocytopenia associated with HIV 
      Neonatal immune thrombocytopenia 
  
 
18 
 
       Alloimmune 
       Autoimmune (e.g., maternal ITP) 
   
   Drug-induced immune thrombocytopenia (including heparin-
induced thrombocytopenia) 
      Post-transfusion purpura 
      Allergy and anaphylaxis 
      Post-transplant thrombocytopenia 
     Nonimmune thrombocytopenias 
      Thrombocytopenia of infection 
       Bacteremia or fungemia 
       Viral infection 
       Protozoal infection 
      Thrombotic microangiopathic disorders 
    
   Hemolytic-uremic syndrome 
       Thrombotic thrombocytopenic purpura 
    
   Bone marrow transplantation–associated microangiopathy 
       Drug-induced 
      Platelets in contact with foreign material 
      Congenital heart disease 
      Drug-induced via direct platelet effects (ristocetin, protamine) 
      Type 2B VWD or platelet-type VWD 
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 Combined Platelet and Fibrinogen Consumption 
Syndromes 
     Disseminated intravascular coagulation 
     Kasabach-Merritt syndrome 
     Virus-associated hemophagocytic syndrome 
 
IMPAIRED PLATELET PRODUCTION 
    Hereditary disorders  
    Acquired disorders 
     Aplastic anemia 
     Myelodysplastic syndrome 
     Marrow infiltrative process 
     Osteopetrosis 
   
  Nutritional deficiency states (iron, folate, vitamin B12, anorexia 
nervosa) 
     Drug- or radiation-induced thrombocytopenia 
     Neonatal hypoxia or placental insufficiency 
 
SEQUESTRATION 
    Hypersplenism 
    Hypothermia 
    Burns 
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This can be further simplified and considered as follows:11 
1. Pseudothrombocytopenia 
2. Congenital thrombocytopenia 
3. Acquired thrombocytopenia 
a. Platelet sequestration 
• - Hypersplenism 
b. Decreased production 
• - Neoplasia (bone marrow infiltration or cytotoxic drugs) 
• - Viruses (EBV, CMV, rubella, varicella, parvovirus) 
• - Megaloblastic anaemia 
c. Increased destruction 
• - Immune-mediated (ITP, neonatal alloimmune 
thrombocytopenia, drug-induced ITP, post-transfusion, 
autoimmune diseases, lymphoproliferative disorders, HIV, 
HCV and Helicobacter pylori infections, HIT 
• - Not immune-mediated (vascular prostheses, DIC, 
TTP/HUS, HELLP, eclampsia) 
This classification certainly allows us to work up with more ease 
from a clinical point of view in that it allows a differential diagnosis to be 
made on the basis of symptoms, findings and blood  counts. 
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Out of these disorders listed,few of the common conditions that are 
encountered in the clinical setting are discussed below with regards to the 
cause of thrombocytopenia in those conditions and their prognosis and 
treatment. 
I.PSEUDOTHROMBOCYTOPENIA: 
Laboratory platelet counts are prone to error. This is due to in vitro 
agglutination of platelets in blood collected into tubes containing 
EDTA12.Hence,a single platelet count that is lower than normal should be 
always confirmed by a second count. It should also be confirmed by 
inspecting the blood film13. “Platelet satellitism”,a phenomenon due to 
adhesion of platelets to polymorphonuclear cells,can also be excluded by 
seeing the smear14. 
II.INFECTIOUS CAUSES: 
Thrombocytopenia is seen in several infections.It is a common cause 
of the bleeding seen in infectious diseases15. 
A.VIRUSES: 
Mild thrombocytopenia is frequently associated with viral 
infection16.Although the pathophysiologic mechanisms are not exactly 
known, a production deficit is probably cited as important in  many of the 
cases. Megakaryocytes containing inclusion bodies are seen in dengue, 
other hemorrhagic fevers, hepatitis,varicella, cytomegalovirus, infectious 
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mononucleosis, chickenpox and parvovirus infections17,18.Even live 
measles virus vaccination can also cause thrombocytopenia19.  
1.DENGUE: 
In the Indian setting dengue is one of the commonest causes of 
transient thrombocytopenia.Though transient,it is often very 
severe.Associated with the plasma leakage that is characteristic of the 
disease,it is an important cause of mortality and morbidity in Indian 
children.INDIA falls under Category A of the WHO South East Asia region 
epidemiological data review.This includes countries where dengue is a 
 Major public health problem 
 Hyperendemicity with  all four serotypes  circulating in urban areas. 
 Leading cause of hospitalization and death among children. 
 Spreading to rural areas. 
In-country geographic expansion is occurring in  India and Cyclic 
epidemics are increasing in frequency 20. 
The dengue viruses are members of the genus Flavivirus and family 
Flaviviridae. Aedes (Stegomyia) aegypti (Ae. aegypti) and Aedes 
(Stegomyia) albopictus (Ae. albopictus) are the two most important vectors 
of dengue.The genome of the dengue virus is composed of seven non-
structural protein (NS) genes and three structural protein genes. Among 
nonstructural proteins, the envelope glycoprotein, NS1, is of diagnostic and 
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pathological importance. Plasma levels of secreted NS1 (sNS1) correlate 
with viral titers, being higher in patients with DHF compared with dengue 
fever21. Moreover, elevated free sNS1 levels within 72 hours of onset of 
illness identify patients at risk of developing DHF. Very high levels of NS1 
protein are detected in acute phase samples from patients with secondary 
dengue infections but not primary infections. This suggests that NS1 may 
contribute to formation of circulating immune complexes, which are 
thought to have an important role in the pathogenesis of severe dengue 
infections22.  
There are four dengue virus serotypes, which are denoted as DENV-
1, DENV-2,DENV-3 and DENV-4. Infection with any one serotype confers 
lifelong immunity to that virus serotype.Although all four serotypes are 
antigenically similar, they are different enough to elicit cross-protection for 
only a few months after infection by any one of them. Secondary infection 
with another serotype or multiple infections with different serotypes leads 
to severe form of dengue (DHF/DSS). 
Dengue virus infection may be asymptomatic or may cause 
undifferentiated febrile illness (viral syndrome), dengue fever (DF), or 
dengue haemorrhagic fever (DHF) including dengue shock 
syndrome(DSS). 
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Course of dengue illness is characterized by three phases-febrile 
phase,critical phase and the recovery phase.As the figure below shows 
clearly,the manifestations are well documented and can be well anticipated 
if diagnosis has been made early serologically. 
Figure 3:The course of dengue illness 
              
FEBRILE PHASE: 
Febrile phase is the initial phase during which dengue presents like 
any other illness,often goes unrecognized because of the gross similarity 
with other infections.High grade fever is present which typically lasts 2-7 
days and is often accompanied by facial flushing, generalized body ache, 
myalgia, arthralgia,skin erythema and headache23.Injected pharynx,sore 
throat and conjunctival injection may be seen in few patients,as also 
anorexia, nausea and vomiting.Tourniquet test may be positive in this phase 
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and positivity increases the probability of dengue24.Monitoring for warning 
signs during this phase is vital to recognize progression to the critical 
phase. 
TABLE 2:WARNING SIGNS IN DENGUE
 
Petechiae,gum bleeds and epistaxis are the usual mild hemorrhagic 
manifestations that are seen in this phase .Gastrointestinal bleeding may 
occur,but is uncommon25.Progressive decrease in total white cell count, is 
probably the only early hematological abnormality. 
CRITICAL PHASE 
On days 3–7 of  the illness, an increase in capillary permeability 
along with increasing hematocrit levels and dropping platelet counts is 
seen26.This is the period of defervesence of fever and is the onset of the 
critical phase,associated with increasing mortality and morbidity.Plasma 
leakage usually lasts 24–48 hours. 
At this point patients without plasma leakage will improve, while 
those with increased plasma leak become worse because of the lost plasma 
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volume. Pleural effusion and ascites may be the clinically recognisable 
evidence of plasma leakage,hence the importance of Chest X-ray and 
abdominal ultrasound for diagnosis.The degree of increase above the 
baseline hematocrit is usually more than 20% in DHF and correlates with 
the disease severity.Lesser degrees of rise are associated with milder 
manifestations. 
Dengue Shock syndrome(DSS) occurs when  critical volume of 
plasma(usually more than 25%) is lost.It is often preceded by warning 
signs and hence in most cases,early identification is possible with careful 
monitoring.Disseminated intravascular coagulation may be triggered by 
prolonged plasma leak and shock. This in turn leads to severe 
haemorrhage.Hematocrit  may thus decrease in severe shock.End organ 
damage in the form of severe hepatitis, encephalitis or myocarditis and/or 
severe bleeding may also develop27. 
Serial monitoring of the platelet count and hematocrit is 
recommended during this phase to identify the onset of recovery phase and 
to guide fluid therapy. 
RECOVERY PHASE: 
In the next 48–72 hours,if the patient survives,a gradual reabsorption 
of extravascular fluid takes place. Appetite returns, general well-being 
improves, gastrointestinal symptoms abate.Hemodynamic status stabilizes 
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and diuresis occurs. Some patients may develop a erythematous rash  
described as“isles of white in the sea of red”28. Bradycardia is common 
during this stage. 
The hematocrit  may sometimes even be lower due to the dilutional 
effect of reabsorbed fluid. Soon after defervescence the white blood cell 
count usually starts to rise but the recovery of platelet count is typically 
later. 
Respiratory distress is likely to occur if excessive intravenous fluids 
had been administered,because of the development of pulmonary oedema 
or congestive heart failure. 
The exact cause of thrombocytopenia in dengue is unknown,but is 
thought to be multifactorial; There is enhanced production of anti-platelet 
and anti-NS1 antibodies in dengue.This is caused by cytokine 
overproduction(Interleukin-6) induced by the virus.There is also aberrant 
immune activation.These antibodies cross-react with human 
platelets29 .Reduced production of platelets in DF and increased destruction 
in DHF may  also be the reasons 30,31. The reduction in the counts may also 
be due to bone marrow suppression induced by the dengue virus 32. Viral 
antigen antibody complex induced destruction of circulating platelets has 
also been documented33. 
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TABLE 3:WHO CLASSIFICATION OF DENGUE INFECTIONS 
AND GRADING OF SEVERITY OF DHF:34 
 
*DHF GRADE III AND IV ARE DSS 
As can be seen from the WHO table,low platelet count is currently 
used as a criterion for the diagnosis of DHF . 
2.HIV:                                                                                                
Thrombocytopenia is a common finding in patients who are infected 
with the human immunodeficiency virus (HIV). Almost one fourth of 
children with  HIV infection exhibit thrombocytopenia within 10 years 
after seroconversion35. In these patients both platelet destruction and 
impaired production are the causes of the decrease in platelet count. 
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Impaired production may be a direct effect of the virus, adverse effects of 
drug therapy, or due to associated  malignancy. Regardless of the degree of 
thrombocytopenia, kinetic studies have shown that patients with HIV have 
a moderate reduction in platelet survival, but all have decreased platelet 
production36. Treatment with zidovudine has been shown to increase 
platelet production in some patients with HIV37. 
3.OTHERS: 
Cytomegalovirus, Ebstein barr virus, Parvovirus and several other 
hemorrhagic viruses are associated with thrombocytopenia but the 
occurrence of these diseases are rare.Marrow suppression induced by the 
virus may be the cause of thrombocytopenia.Chronic active hepatitis may 
induce thrombocytopenia by causing hypersplenism which has been  
reported in literature. 
B.BACTERIAL:  
Septicemia,miliary tuberculosis, leptospirosis,typhoid and 
mycoplasma pneumonia are all known to cause thrombocytopenia38. 
I.SEPTICEMIA:                                                                            
Thrombocytopenia is a well recognized complication seen in both 
gram positive as well as gram negative sepsis.Increased platelet destruction 
is characteristically seen in Meningococcal septicemia and often triggers 
DIVC in this clinical setting.Hemophagocytic histiocytosis is also seen in 
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septicemia and may contribute to the thrombocytopenia.Escherichia coli 
sepsis is associated with the hemolytic uremic syndrome. Platelet 
adherence to damaged vascular surfaces is seen in meningococcemia and 
other bacterial infections33.Endotoxin, exotoxin and  platelet activating 
factor may all damage the  platelets,then  resulting in increased clearance in 
the spleen. 
II.ENTERIC FEVER: 
Thrombocytopenia as a part of enteric fever has been documented by 
several workers39.It is usually seen in complicated enteric fever and in 
multi drug resistant cases.This could be due to bone marrow suppression or 
due to liver cell dysfunction.Bleeding manifestations may also be 
associated with  decrease in the platelet counts.Complications may be 
explained by  the wide array of cytokines and other inflammatory 
mediators that are induced by  Salmonella . 
III.OTHER BACTERIAL INFECTIONS: 
Leptospirosis is the classical example of PUO with high fever,renal 
compromise,elevated liver enzymes,jaundice and thrombocytopenia. 
Typhus group of infections  is also associated with increased capillary 
permeability,thrombocytopenia,bleeding manifestations and skin lesions 
and is  a close differential diagnosis for dengue fever.Mycoplasma and 
Tuberculosis may rarely have a decreased platelet count. 
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C.PROTOZOAL: 
MALARIA: 
Malaria  is  the classical  protozoan disease very commonly 
associated with anemia and thrombocytopenia. Human platelets have been 
demonstrated to contain plasmodia species.Thrombocytopenia occurs in 
over 80% of patients with malaria. Experimental data suggested immune 
mediated destruction with elevated platelet activated immunoglobulin to be 
the cause. However in 1993, it was demonstrated that ultra structural 
changes in platelets, as well as the high level of parasitemia were the cause 
for thrombocytopenia. Antibodies against platelet absorbed microbial 
antigens are also responsible40. 
III.ITP:                                                                                                              
Idiopathic Thrombocytopenic Purpura is the prototype of paediatric 
destructive thrombocytopenias.Other causes of consumption of platelets are 
autoimmune disorders including SLE. 
ITP is the most common immune mediated thrombocytopenia in 
children41.   ITP can be acute or chronic.Acute form is commoner in 
children and is seen in children 2-6 yrs old where platelets return to normal 
in 6 months42.  The typical case of symptomatic childhood ITP is 
characterized by the sudden appearance of bruising or mucocutaneous 
bleeding in an otherwise healthy child,often after a preceding viral 
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illness.Association with mumps,measles and rubella has been 
documented.It is basically a diagnosis of exclusion and there should be no 
lymphadenopathy or hepatosplenomegaly. The severity of bleeding 
symptoms in childhood ITP is proportionate to the degree of 
thrombocytopenia. 
Pharmacologic therapy is not generally indicated for children who 
have mild to moderate thrombocytopenia as they are unlikely to have 
serious bleeding 43.Moderate restriction of activity is all that is needed to be 
advised.The primary treatment options for the newly diagnosed patient in 
severe cases are corticosteroids,Intravenous immunoglobulin, and anti-
Rho(D) immune globulin44.There is no role for platelet transfusion as this 
will lead usually to a drop in the platelet counts,rather than increase,by 
triggering alloimmunisation. 
IV.MARROW RELATED DISORDERS: 
INFILTRATIVE DISORDERS: 
In leukemia,especially ALL(Acute Lymphoblastic Leukemia),and 
also in Hodgkins lymphoma,Non Hodgkins lymphoma,Gauchers 
disease,Osteopetrosis,Myelofibrosis and Histiocytosis, thrombocytopenia is 
seen.Physical replacement of marrow  by the tumor cells leading to 
decreased platelet production is the etiology  in many cases.But  inhibitory 
factors produced by the infiltrating cells are toxic to the cells of the 
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megakaryocytic lineage which may also contribute. The marrow shows 
decreased megakaryocytes, which may be larger than normal.This is a 
compensatory physiologic response to the infiltrative process. Autoimmune 
thrombocytopenia, DIVC, and thrombotic microangiopathy may all 
contribute to thrombocytopenia in malignancy.45 
HEMOPHAGOCYTIC SYNDROME: 
This is a condition quickly gaining prominence among clinicians in 
recent times.It is a correctable cause of hematological abnormalities if 
identified early.Guidelines for diagnosis have been established.The 
hemophagocytic syndrome is characterized by pancytopenia and 
morphologic evidence of phagocytosis of red cells, granulocytes, and 
platelets by reactive macrophages. It could be fatal if untreated.It is 
characterized by high fever, weight loss, prominent hepatosplenomegaly, 
severe pancytopenia and elevated liver enzymes46.Viral etiology has been 
proposed.Severe, but potentially reversible, hemophagocytosis can be seen 
in patients with certain unusual infections (e.g., Babesiosis, Ehrilichiosis). 
Hemophagocytosis has also been observed in patients with SLE, Still’s 
disease, and HIV infection47. Treatment should be directed to the 
underlying illness, with steroids and blood product support as and when 
needed. 
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HYPERSPLENISM: 
Hypersplenism is a syndrome characterized by splenomegaly and 
any or all of the following cytopenias: anemia, leucopenia, or 
thrombocytopenia.The cytopenias will be corrected following 
splenectomy48.Splenomegaly is almost always present in hypersplenism. 
Thalassemia is the most common paediatric hemolytic disorder that can 
present with hypersplenism.Increased splenic platelet pooling is the cause 
of thrombocytyopenia in hypersplenism49. A massively enlarged spleen can 
hold > 90% of the total platelet mass. In hypersplenism, the platelet count 
is usually between 50-150×109/L, and almost never <20×10 9/L. Therefore, 
patients with hypersplenism almost never have evidence of bleeding 
attributable to thrombocytopenia, nor do they need specific interventions to 
raise the platelet count.  
OTHER MARROW CAUSES: 
  Aplastic anemia involves multiple hematopoietic lineages, although 
isolated thrombocytopenia can be the presenting feature50. 
There are also numerous congenital disorders and syndromes that 
can be associated with thrombocytopenia.They are rare in  clinical 
settings.Some of these conditions are Wiskott Aldrich syndrome variants 
and other X-linked recessive thrombocytopenias, Congenital 
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amegakaryocytic thrombocytopenia, Thrombocytopenia with absent radius 
syndrome and May Heggelin anomaly.51 
V.OTHERS: 
There are several other conditions which also can have 
thrombocytopenia.These include hemorrhagic snake bite,drug induced 
thrombocytopenia(including heparin induced thrombocytopenia),severe 
iron deficiency anemia,megaloblastic anemia,heart diseases,artificial 
valves,Kasabach Merritt syndrome,decompensated liver disease with portal 
hypertension and Von Willebrands disease. 
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FIGURE 4:CORRELATION BETWEEN THE PLATELET COUNT 
AND THE RISK OF BLEEDING: 
 
Correlation between the platelet counts and bleeding risk shows 
increased bleeding with lower counts.    
RELATIONSHIP BETWEEN PLATELET COUNT AND BLEEDING 
RISK52 
In several clinical conditions,there is poor correlation between the 
counts and the incidence of bleeding.But in general,the risk of bleeding 
does not increase until the platelet count falls significantly below 1 
lakh/L.A platelet count greater than 50000/L is adequate for hemostasis in 
most circumstances and most of these patients are only incidentally 
diagnosed.Patients who have moderate thrombocytopenia between 30 and 
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50000/L may only develop trivial bruising or bleeding,even with 
significant trauma.  
In patients with platelet counts between 10000-30000/L,there may be 
risk for excessive bleeding only with significant trauma. Spontaneous 
bleeding typically does not occur unless the  platelet counts are less than 
10000/L.Petechiae and spontaneous bruising may be seen in these 
patients,but even they may be entirely asymptomatic.It appears that the 
platelet count must be less than 5000 to cause critical spontaneous bleeding 
(eg,atraumatic intracranial hemorrhage[ICH]). 
Patients who have destructive thrombocytopenias have less severe 
bleeding symptoms than patients who have a similar degree of 
thrombocytopenia due to impaired platelet production.This is because of 
the brisk production of younger platelets in destructive 
thrombocytopenias,and thus less severe bleeding 
symptoms.Comparatively,in conditions where  there is  impaired 
production of platelets in the marrow,the circulating population of platelets 
is older and ineffective47.Hence,the bleeding manifestations seen in these 
conditions are also much more severe. 
INVESTIGATIONS: 
The figure shown below is a useful diagnostic workup plan for 
thrombocytopenia. 
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Bleeding diathesis     Platelet count     Routine test 
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HIT 
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Not isolated 
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FIGURE 5: WORKING DIAGNOSTIC ALGORITHM FOR 
THROMBOCYTOPENIA:53 
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In evaluating a patient with thrombocytopenia, a key step is to first 
rule out "pseudo-thrombocytopenia," particularly in a patient without an 
apparent cause for the thrombocytopenia. Once pseudothrombocytopenia is 
ruled out,if a low platelet count is obtained in EDTA-anticoagulated blood, 
a blood smear should be evaluated and a platelet count determined in blood 
collected into sodium citrate or heparin tube, or a smear of freshly obtained 
anticoagulated blood, such as from a finger prick, can be examined. 
The diagnostic work up of patients with thrombocytopenia should 
then include the following battery of investigations: 
1. Complete Blood Count: Presence of other cytopenias should be looked 
for.Mean platelet volume needs to be assessed. A mildly elevated MPV is 
consistent with a destructive cause. 
A. Total count, Differential Count 
Leucopenia-in early dengue before IgM ELISA is positive 
Leukocytosis-predominant neutrophils indicate bacterial infection,    
septicemia, predominant lymphocytosis in Tuberculosis. 
2. E.S.R: elevated in most of the infections, malignancies, anemia .It is a 
non specific test. 
3. Peripheral blood smear54: The ability to assess the Peripheral blood 
smear accurately is invaluable. Malarial parasites and gametocytes, Dohle 
bodies, thrombocytopenia, abnormal cell morphology in leukemia should 
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be carefully looked for. The smear should be examined to estimate the 
platelet number (1 platelet/high power field=platelet count of 10-
15000).Platelet clumps,variation in the size of platelets,evidence of 
hemolysis in the form of spherocytes and schistocytes are to be looked 
for.Direct coombs test will be needed if the smear is suggestive of 
hemolysis.Presence of malarial parasites and ring forms in the RBC’s are 
important in endemic areas. 
4. Blood sugar, urea, creatinine -acute renal injury may be caused by 
infections like malaria and leptospirosis,septic shock,DSS. 
5. Liver function tests- hyperbilirubinemia and elevated liver enzymes are 
seen in malaria (esp. falciparum), leptospirosis,septicemia,dengue. 
6. Urine albumin, deposits-renal failure (malaria, leptospirosis), Urinary 
tract infections 
7. Chest X Ray- pleural effusion in dengue, pulmonary tuberculosis 
8.Ultrasonography-hepatomegaly,splenomegaly.Gallbladder 
pericholecystic edema with wall thickening is suggestive of dengue.Ascites 
can also be there in dengue. 
9. Widal- serological method for evaluation of typhoid fever.Should be 
done in the second week of fever. 
10.dengue panel-NS1 is positive from days 2-9 of the illness.IgM Dengue 
ELISA is positive after 5th day of fever and rising titres are indicative of 
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dengue.Similarly IgG Dengue ELISA-four fold increase in titre is highly 
suggestive of dengue. 
TABLE 4: INTERPRETATION OF DENGUE DIAGNOSTIC 
TESTS:55 
 
11. IgM ELISA leptospiral antibodies-Acute toxic presentation with 
conjunctival suffusion, renal failure and abnormal liver function tests 
12. Blood culture – at least 3 blood culture samples to be taken, special 
technique is required for fastidious organisms to grow. 
13. Urine culture and sensitivity-urinary tract infections 
14. Bone marrow examination: Leukemia, lymphoma, Pyrexia of 
unknown origin,pancytopenia.In patients with fever and thrombocytopenia 
with renal and liver parameters being abnormal, it is very important to 
consider a bone marrow biopsy which may help to differentiate inadequate 
production from excessive destruction/consumption as the predominant 
cause of thrombocytopenia 56. A bone marrow examination is not necessary 
in most cases of isolated unexplained thrombocytopenia in children.In 
general, a bone marrow examination is indicated for pancytopenia when 
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there are blasts in peripheral smear,and systemic symptoms such as fever, 
fatigue, weight loss,or bone pain. 
ROLE OF PLATELET TRANSFUSIONS IN 
THROMBOCYTOPENIA 
In 1910, W.W Duke,a JOHNS HOPKINS physician demonstrated 
the relation of blood platelets to bleeding and demonstrated for the first 
time that platelet transfusion could have a role in relieving it57.  But until 
1950,reliable methods for platelet preparation were not developed.Even in 
1970,only specialized medical centers had facilities for platelet 
transfusion.However,today,platelets are easily available on an emergency 
basis. 
Guidelines for platelet transfusions of children and adolescents are 
comparable to adult guidelines as shown in table 5.When platelet levels fall 
to <20000/L ,spontaneous bleeding risk increases markedly, if serious 
complications (infection, organ failure, clotting abnormalities, or anemia) 
are present. In this setting, prophylactic transfusions are given to maintain a 
count of >20000/L. However, in practice, severe thrombocytopenia  
commonly occurs in association with the complications of fever, 
antimicrobial therapy, active bleeding, disseminated intravascular 
coagulation, and other severe clotting abnormalities, situations in which 
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transfusions are given to maintain relatively high counts.Hence guidelines 
are arbitrary and have to be judiciously applied in the clinical setting.  
Long term and repeated transfusions in any patient may lead to 
alloimmunization and refractoriness. The goal of most platelet transfusions 
is to raise the platelet count to >50000/L for older children and  >100000/L 
for neonates. This can be achieved consistently in children weighing up to 
30 kg by infusing 10 mL/kg of standard (unmodified) Platelet concentrates, 
obtained either from processing whole blood units or by platelet pheresis. 
For children weighing more than 30 kg, the appropriate dose is 3–6 pooled 
whole blood–derived  units or 1 apheresis unit. Platelet concentrates should 
be transfused as rapidly as the patient's overall condition permits, certainly 
within 2 hr. Patients requiring repeated platelet transfusions should receive 
leukocyte-reduced blood products, including platelet concentrates, to 
diminish alloimmunization and platelet refractoriness and reduce the risk of 
transfusion-transmitted cytomegalovirus infection. 
Transfusion of 10 mL/kg of an unmodified platelet concentrate is 
adequate because it adds to increase the platelet count by 10000/L. 
Moreover, 10 mL/kg is not an excessive transfusion volume, provided the 
intake of other IV fluids is monitored and adjusted.However in 
dengue,even this volume can contribute to fluid overload with no proven 
benefit to patient outcome.Hence routine platelet transfusions are not 
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recommended in Dengue by WHO. It may be considered only in very 
severe thrombocytopenia less than 10,000/L.58 
TABLE 5   -- GUIDELINES FOR PAEDIATRIC PLATELET 
TRANSFUSIONS59 
CHILDREN AND ADOLESCENTS 
    Platelets < 50 × 109/L and bleeding 
     < 50 × 109/L and an invasive procedure 
     < 20 × 109/L and marrow failure with hemorrhagic risk factors 
    < 10 × 109/L and marrow failure without hemorrhagic risk factors 
   
  At any count, but with Platelet dysfunction plus bleeding or an 
invasive procedure 
 
INFANTS WITHIN THE FIRST 4 MONTHS OF LIFE 
    Platelets< 100 × 109/L and bleeding 
     < 50 × 109/L and an invasive procedure 
     < 20 × 109/L and clinically stable 
     < 100 × 109/L and clinically unstable 
   
 At any count, but with Platelet dysfunction plus bleeding or an 
invasive procedure 
 
 In most infectious diseases, the thrombocytopenia is often transient 
and seldom requires platelet transfusions. Treating the underlying condition 
will result in drastic improvement of platelet count and its complications.  
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STUDIES  ON  THROMBOCYTOPENIA: 
 A prospective study was conducted in Hayat Shaheed 
hospital,Peshawar  by Ali jan et al,from June 1995 to December 
1996.100 children with thrombocytopenia were studied.The differential 
diagnosis and the bleeding manifestations were documented.ITP was 
found to be the leading diagnosis followed by aplastic anemia and 
leukemia.There was good response to steroids in the study group60. 
 Another prospective study in Shri Ganga Ram hospital,Delhi by 
Sachdev et al was done to evaluate the outcome of children with 
thrombocytopenia in the paediatric intensive care unit.138 patients 
were included over a 7 month study period. Patients requiring 
cardiopulmonary resuscitation or with circulatory shock, coagulopathy, 
sepsis and with more severe disease were found to have higher risk of 
developing thrombocytopenia. Drop in platelet counts >27% and 
thrombocytopenia were found to be independently related to 
mortality61. 
 A study done in University college of Medical Sciences,Delhi by Mittal 
et al was done during the 2010 Dengue epidemic to assess the clinico 
hematological profile and platelet trends in the admitted children.It was 
a retrospective study which assessed 135 children.The study concluded 
that complications and mortality were low.There was also higher age of 
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presentation of dengue cases compared to previous studies and more 
DHF cases indicating an increase in the severity of disease.The platelet 
recovery time was found to be  not influenced by the disease 
category62. 
 A study done in St Louis University,USA assessed the implications of 
thrombocytopenia in the paediatric ICU By Krishnan et al63.They found 
an incidence of 17.3% of thrombocytopenia among PICU patients and 
that a 10% drop in platelet count in these patients was associated with 
increase in the hospital stay and mortality.
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4. MATERIALS AND METHODS: 
STUDY DESIGN: 
Descriptive,Cross sectional study. 
STUDY POPULATION: 
This study was done on children who were admitted to the children 
medical ward of Tirunelveli Medical College Hospital during the period 
from December 2011 to April 2012. 112 consecutive  patients who satisfied 
the following inclusion criteria were studied.Prior ethical committee 
approval was obtained for the study.The total number of admissions during 
the study period was 702. 
METHODOLOGY: 
INCLUSION CRITERIA : 
1. The patients of both sexes aged  2 MONTHS TO 12 YEARS. 
2. Patients with platelet counts less than 1 lakh anytime during the 
course of hospital stay,irrespective of the cause for admission. 
EXCLUSION CRITERIA : 
1. Patients with spurious thrombocytopenia-lab induced errors where 
immediate repeat platelet counts or the peripheral smear did not grossly 
correlate with the first count were excluded 
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2. Patients who were earlier diagnosed to have conditions that are known 
to cause thrombocytopenia (e.g. known cases of hematological 
malignancies, aplastic anemia, MDS, ITP).  
3. Patients who have already received platelet transfusion prior to 
admission. 
4. Patients who were very sick at admission or expired within few hours of 
admission,who could not be subjected to the full set of investigations. 
STUDY PROTOCOL:                     
Once the patients were included in the study,data regarding the 
patient was entered into preset proforma as regards to the history,general 
and systemic examination,Hess test and  vital signs . The bleeding 
manifestations patients presented with or developed during their course in 
hospital were recorded.An awareness questionnaire on dengue with three 
simple questions was also included for the parents.Informed consent was 
obtained. 
Following  investigations were done for all patients as a  1ST PANEL: 
1. CBC including TC,HB,ESR,PCV.The trend of platelet counts was 
monitored 12-24 hourly till a count of 1 lakh was reached,with or 
without intervention. 
2. PERIPHERAL SMEAR FOR MP/MF AND FOR THE BLOOD 
PICTURE 
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3. Blood sugar, urea, creatinine,serum bilirubin,liver enzymes 
4. IgM DENGUE ELISA,NS1 ELISA AND IgG DENGUE ELISA-these 
were done twice;1st sample on the day of onset of thrombocytopenia and 
the second one as a convalescent sample to identify positivity and to 
quantitate the rise in titre. 
5. BLOOD WIDAL,URINE C/S,BLOOD C/S. 
6. CHEST X RAY AND USG ABDOMEN 
 If the 1st panel did not reveal a diagnosis,a 2nd panel of investigations 
were done: 
1. IgM ELISA FOR LEPTOSPIROSIS, 
2. BONE MARROW STUDY 
3. Antinuclear antibodies,PT,aPTT,hepatitis screening,CRP  were done 
depending on the clinical scenario. 
Once the specific diagnosis was reached, patients were treated for it 
specifically and symptomatically (Mechanical ventilation, shock 
correction,steroids).Blood products were transfused as per the treating 
physician’s discretion. The proportion of study patients requiring 
interventions to improve platelet count like platelet transfusion, steroids and 
the reason for such interventions were recorded.  
The questions in the awareness questionnaire are: 
1. Have you heard the word “dengue”? 
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2. Tell the signs and symptoms of the disease 
3. How is the disease transmitted? 
The answers given by the parents were also documented. 
The gathered data was fed into a master chart(annexure) to aid 
statistical analysis. 
The causes of fever with thrombocytopenia are so numerous, a 
simple workable classification is presented  – 
1. Viral causes : Dengue; Parvo-B19; hepatitis, HIV,CMV 
2. Bacterial causes : Gram positive and negative septicemia, miliary 
tuberculosis,leptospirosis, typhoid etc. 
3. Protozoal causes : Malaria. 
4. ITP/TTP/HUS 
5. Others : Leukemia, lymphoma,hypersplenism,aplastic anemia etc.. 
6. DIVC-sepsis,snake bite.  
7. Connective tissue disorders-SLE.  
COLLABORATING DEPARTMENTS: 
Departments of Biochemistry,Microbiology and Pathology; 
Tirunelveli Medical College, Tirunelveli. 
LIMITATIONS OF THE STUDY: 
1. Study was done during the seasonal period for infectious 
diseases.Hence incidence of infectious diseases might have been 
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higher 
2. Complete bleeding profile in the form of PT,aPTT  were not done for 
all the patients. 
3. Incidence of malaria is very low as the region is not an endemic 
area.Hence the data on malaria is subject to confounding. 
4. Drug induced thrombocytopenia was not studied. 
5. Viral serology was not done due to financial constraints. 
STATISTICAL ANALYSIS : 
Data   was entered into an  Excel Spreadsheet and analysed using 
SPSS Version 16. Using this software, frequencies, percentages, means, 
standard deviations, chi square  test, paired t test, unpaired t test correlation 
were applied. A 'p' value less than 0.05 is considered significant. 
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5. OBSERVATIONS AND RESULTS 
Total number of admissions during the study period in children 
medical ward is 702.Number of patients who had thrombocytopenia or 
developed it subsequently during the course of hospital stay is 112(after 
application of the exclusion criteria),which means one among every 6.25 
children admitted developed thrombocytopenia.(15.95%incidence) 
In 107 patients a cause for the thrombocytopenia could be identified with 
the panel of investigations applied.5 patients were left undiagnosed despite 
full battery of investigations.  
TABLE 6: AGE WISE DISTRIBUTION AND MORTALITY                    
S.NO AGE 
Frequency 
(n=112) 
Percent Mortality Percent p value 
1 <1 year 11 9.8 5 45.5 0.073 
2 1-5yrs 33 29.5 1 3  
3 6-10yrs 53 47.3 2 3.8  
4 >10 yrs 15 13.4 0 0  
                      
The commonest age group of presentation of thrombocytopenia 
among the study group  is 6-10 years,constituting 47.3% of the 
cases.Mortality is highest among infants.Out of 11 infants studied,5 
expired(45.5%).But this is not statistically significant(p>0.05).Mean age of 
  
 
 
presentation is 6.56 years(SD=3.49).The mean age of expired children is 
2.8years which is statistically significant(p<0.05). 
TABLE 7: SEX WISE DISTRIBUTION OF THROMBOCYTOPENIA 
S.NO SEX 
NO OF PATIENTS 
(N=112) 
PERCENTAGE 
1 MALE 53 47.3 
2 FEMALE 59 52.7 
 
52.7% of the study population were girl children.There is no 
particular sex predilection for thrombocytopenia.The Male female ratio is 
0.89:1. 
TABLE 8: OUTCOME OF CHILDREN WITH 
THROMBOCYTOPENIA 
S.NO OUTCOME N=112 PERCENTAGE 
1 DISCHARGE 97 86.6 
2 DEATH 8 7.1 
3 REFERRED 7 6.3 
 
8 patients expired during the course of the hospital stay.The mortality 
rate is 7.1%.For  7  patients there was no significant improvement in 
platelet count till discharge because of the underlying disease process as in 
leukemia,hypersplenism and ITP and were referred to higher institutions.In 
all the other patients(86.6%) the platelet count improved prior to discharge 
and the thrombocytopenia was only transient.              
  
 
FIGURE 6:COMPARISON OF AGE WISE INCIDENCE AND THE 
MORTALITY IN EACH AGE GROUP
FIGURE 7: SEX WISE DISTRIBUTION            
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TABLE 9: ETIOLOGY AND DISEASE WISE MORTALITY OF 
THROMBOCYTOPENIA                                   
s.no DIAGNOSIS Frequency(n=112) Percent Death(n=8) % 
1 Dengue 
fever(DF) 
36 32.1 0 0 
2 DHF 21      18.7 0 0 
3 DSS 9        8 4 44.4 
4 Enteric 13 11.6 0 0 
5 Dengue/enteric 
co infection 
                           4        3.6 0 0 
6 Malaria 3 2.7 0 0 
7 ALL 5 4.5 0 0 
8 Septicemia 5        4.5 2 40 
9 Undiagnosed 5 4.5 0 0 
10 Miscellaneous 11 9.8 2 18.2 
The commonest etiology for newly diagnosed thrombocytopenia 
among children admitted is Dengue.Total dengue cases were 66,comprising 
58.8% of the study population.Among the dengue cases,dengue fever with 
or without hemorrhage(DF) was most common(32.1%).The second 
commonest diagnosis was enteric fever.11.6% of the thrombocytopenia 
cases had enteric fever.In 5 cases,a final diagnosis could not be 
reached(4.5%),which is within allowable limits.All  3 cases of malaria were 
due to Plasmodium vivax.All cases of leukemia were acute lymbhoblastic 
leukemia(ALL).4 cases were due to co infection with both dengue and 
enteric fever,one of which also had urinary tract infection. 
  
 
 
Leading cause of mortality in the study population is dengue shock 
syndrome(DSS),causing  4 out of the 8 total deaths.DSS comprised only 8% 
of cases with thrombocytopenia,but had the highest mortality rate of 
44.4%.The next leading cause of mortality was septicemia. 
 TABLE 10:MISCELLANEOUS CAUSES OF 
THROMBOCYTOPENIA 
S.NO DISEASE 
FREQUENCY 
(n=11) 
1 ITP 2 
2 Snake bite 2 
3 Leptospirosis 1 
4 Hepatitis 1 
5 HIV 1 
6 Lymphoma 1 
7 Aplastic anemia 1 
8 Hemophagocytic syndrome 1 
9 Hypersplenism 1 
 
11 cases had rarer diagnosis.2 of these patients died.Cause of death in 
one case was snake bite with severe bleeding manifestations probably 
DIVC.The other death was a diagnosed case of hemophagocytic syndrome 
with elevated ferritin and triglycerides and a marrow picture showing 
presence of histiocytes. 
 
 
  
 
 
FIGURE 9: CHART SHOWING THE ETIOLOGY AND DISEASE 
WISE MORTALITY 
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TABLE 11: ETIOLOGY IN 107 DIAGNOSED CASES 
DIAGNOSIS FREQUENCY PERCENTAGE 
INFECTIVE 94 87.9 
NONINFECTIVE 13 12.1 
TOTAL 107 100 
Infections caused most of the thrombocytopenia.Commonest non 
infective cause was ALL.  
TABLE 12:COMPARISON OF PREHOSPITAL TREATMENT 
RECEIVED AND OUTCOME 
s.no. Pre hosp 
No. of 
cases(n=84) 
Deaths 
n=8(%) 
Adequacy of treatment 
received(%) 
1 
Government 
hospitals 
34(40.48) 1(2.9) 76.5 
2 Phc’s 3(3.57) 0 33.3 
3 
Private 
hospitals 
47(55.95) 5(10.6) 68.1 
 
Among the study group,75% were referred cases.6  of the total 8 
deaths were among referred cases.The highest number of referrals were 
from private institutions(55.95%),10.6% of whom expired.The adequacy of 
treatment received was assessed by the proper administration of intravenous 
fluids,antibiotics, blood products and early referral.District headquarters 
government hospitals have adequately treated and referred patients(76.5%). 
 
  
 
 
TABLE 13:   FEVER DURATION AT ADMISSION AND 
OUTCOME 
S.NO. 
fever in days 
on adm 
Frequency 
n=112 
Percentage 
Deaths 
n=8 
%deaths 
1 1-4 days 41 36.6 3 7.3 
2 5-7days 50 44.6 3 6 
3 8-10 days 10 8.9 1 10 
4 >10 days 6 5.4 0 0 
5 afebrile 5 4.5 1 20 
p=0.169 
44.6% of the children presented with fever of 5-7 days duration.5 
cases had no fever at admission.There is no correlation between early 
presentation and the outcome(p>0.05).Mean duration of fever at admission 
is 5.69 days.(SD=3.03)  
 
  
  
 
FIGURE 10:COMPARISON OF OUTCOME AMONG REFERRAL 
FIGURE 11: COMPARISON OF NUMBER OF DAYS OF FEVER 
AT ADMISSION AND THE MORTALITY
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FIGURE 12:  DURATION OF HOSPITALISATION AS INDICATOR 
OF MORBIDITY AND MORTALITY 
 
 
Mean duration of hospital stay in the study group  is 6.15 
days.Children who expired had a significantly(p<0.05)  short hospital 
stay(2.38 days) compared to survivors(6.44 days),indicating they were 
probably very sick at admission. 
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TABLE 14: TOTAL DURATION OF FEVER AND OUTCOME 
S.NO. 
Total days 
of fever 
FREQUENCY 
n=112 
% 
Death 
n=8 
% 
p=0.383 
1 <4 days 12 10.7 3 25 
2 5-7 53 47.3 2 3.8 
3 8-10 24 21.4 1 4.1 
4 10-15 days 14 12.5 0 0 
5 >15 days 4 3.6 1 25 
 
Mean duration for which fever lasted is 7.69 days(SD=3.498).47.35% 
children became afebrile after 5-7 days. Children who had prolonged fever 
more than 15 days had the worst outcome(25% mortality).But this is not 
statistically significant(p=0.383) 
                  
TABLE 15: REPORTS OF AWARENESS STUDY 
S.NO. parameter no of parents  % 
1 heard of dengue 43 38.4 
2 signs and symptoms 20 17.9 
3 Knew transmission 29 25.9 
4 Complete knowledge 12 10.72 
Only 38.4% of the parents had ever heard of the word dengue.17.9% 
knew the signs and symptoms of the disease and 25.9% knew that the 
disease was spread by mosquitoes.Only 10.7% parents had the basic 
knowledge about the disease that is expected of a layman,indicating poor 
awareness of the disease. 
  
 
FIGURE 13:COMPARISON OF TOTAL DAYS OF FEVER AND MORTALITY
FIGURE 14:COMPARISON OF THE AWARENESS TRENDS
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TABLE 16:  SYMPTOM ANALYSIS OF CASES BASED ON 
ETIOLOGY 
Features 
total 
n=112(%) 
dengue 
n=66(% ) 
enteric 
n=13(% ) 
D/E  
n=4(%) 
ALL 
n=5(%) 
sepsis 
n=5(%) 
Fever 107(95.5) 66(100) 13(100) 4(100) 5(100) 5(100) 
abd pain 59(52.7) 35(53) 9(69.2) 3(75) 1(20) 0 
Vomiting 73(65.2) 42(63.6) 11(84.6) 3(75) 2(40) 4(80) 
Cough 42(37.5) 23(34.9) 3(23) 3(75) 1(20) 5(100) 
Myalgia 60(53.6) 35(53) 6(46.2) 2(50) 3(60) 0(0) 
p>0.05 
The most common presenting symptom among the study group is 
fever(95.5%) with vomiting being the second most common 
symptom(65.2%).All the major diagnosed diseases,including leukemia had 
fever.Abdominal pain was most common in dengue/enteric co infection 
while vomiting was most common among enteric fever cases. None of these 
symptoms are statistically significant as far as outcome is 
concerned(p>0.05).                              
76.1% of children with vomiting had bleeding manifestations.This is 
statistically significant(p=0.003). 
 
 
 
 
 
  
 
 
TABLE 17:CLINICAL SIGNS IN THE VARIOUS DISEASES 
S.NO. Features Total  
n=112(%) 
dengue 
n=66(% ) 
enteric 
n=13(% ) 
D/E 
n=4(%) 
sepsis 
n=5(%) 
1 abd 
distension 
28(25)    
p =0.001 
16(24.2) 3(23) 1(25) 2(40) 
2 abd 
tenderness 
18(16.1)   12(18.2) 3(23) 1(25) 0 
3 Oliguria 15(13.4) 6(9.1) 2(15.4) 1(25) 3(60) 
4 Puffy face  27(24.1) 16(24.2) 2(15.4) 0 2(40) 
5 pedal edema 11(9.8)  
p=0.006 
6(9.1) 1(7.7) 0 0 
6 Erythema/ 
flush 
54(48.2) 38(70.4) 5(9.3) 3(5.6) 1(1.9) 
 
Erythematous flush was present in 48.2%  of the cases.70.4% of 
dengue cases had erythematous rash.Oliguria,facial puffiness and 
abdominal distension were the commonest in cases with 
septicemia.Enteric/dengue co infection cases had more abdominal 
tenderness compared to other cases.Abdominal distension and pedal edema 
were significantly associated with low platelet counts, bleeding 
manifestations,increased transfusion needs and a  poor outcome(p<0.05). 
 
  
 
 
FIGURE 15:COMPARISON OF THE CLINICAL SYMPTOMS 
BETWEEN DENGUE AND ENTERIC FEVER 
 
FIGURE 16:COMPARISON OF THE CLINICAL SIGNS BETWEEN 
DENGUE AND ENTERIC FEVER
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TABLE 18:PREDICTORS OF MORTALITY IN VARIOUS 
DISEASES 
features 
total 
n=112(% 
of  n) 
death 
n=8(% ) 
p value 
outcome 
Dengue 
deaths            
n=4(% ) 
septicemia 
deaths 
n=2(% ) 
altered sensorium 49(43.8) 8(100) 0.001 4(100) 2(100) 
tachycardia 48(42.9) 8(100) 0.001 4(100) 2(100) 
tachypnea 20(17.9) 8(100) 0.000 4(100) 2(100) 
shock 18(16.1) 8(100) 0.000 4(100) 2(100) 
seizure 13(11.6) 3(37.5) 0.018 1(25) 2(100) 
mech vent 7(6.3) 6(75) 0.000 2(50) 2(100) 
inotrope 8(7.1) 7(87.5) 0.000 3(75) 2(100) 
narrow pulse 
pressure<20 
19(17) 2(25) 0.484 1(25) 1(50) 
malnutrition 63(56.3) 1(12.5)  0.041 1(25) 0 
 
In children with thrombocytopenia, the presence of Altered 
sensorium,tachycardia,tachypnea,shock at presentation,seizures were 
all significantly associated with low platelet counts,bleeding and 
mortality(p<0.05).Children requiring inotrope support,mechanical 
ventilation  also had  poor outcome(p<0.05).The mortality was also 
significantly high(p<0.05) in malnourished children with 
thrombocytopenia .In fact ,the mean weight of the expired children was 
only 10kg compared to 17kg in survivors.Hence,all these factors are to 
be considered significant predictors of mortality. Narrow pulse pressure 
has not significantly affected the outcome.Occurence of seizures in 
cases with septicemia and thrombocytopenia  had strong correlation 
with death(100%) . 
 
  
 
 
FIGURE 18:COMPARISON OF  PREDICTORS OF MORTALITY
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 TABLE 19: PLATELET TRENDS DURING  HOSPITAL STAY 
Platelet 
Adm 
(%) 
Repeat 1(%) 
p=0.189 
Repeat 2(%) 
p=0.004 
Repeat 
3(%) 
Repeat 
4(%) 
<10000 2.7 0.9 0.9 1.8 4.5 
11000-20000 8 12.5 9.8 7.1 3.6 
21000-50000 35.7 26.8 14.3 8.9 3.6 
51000-100000 45.6 36.6 27.7 11.6 5.4 
>1 lakh 8 23.2 47.3 70.5 83 
 
FIGURE 17:GRAPH SHOWING THE PLATELET TRENDS 
DURING  VARIOUS STAGES OF HOSPITAL STAY 
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Most patients at admission(45.6%)  had a platelet count in the range 
of 50,000-1 lakh. Single lowest count reached by a patient was 6000µ/L. 
Mean platelet count at admission was  61017 µ/L.Platelet trend analysis 
show a significant upward graph indicating that most thrombocytopenia 
was transient.  
Among the platelet counts,the initial values were not significantly 
related to the mortality while the second repeat platelet value had a 
significant bearing on the outcome(p<0.05).Thus,rather than the absolute 
values,it is the drop in counts which is associated with poor outcome. 
  
  
 
 
TABLE 20:TYPES OF BLEEDING MANIFESTATION 
 
 
 
 
 
 
Bleeding manifestations were seen in a total of 67 
patients(59.8%).GI bleed was the commonest bleeding manifestation 
associated with thrombocytopenia,seen  in total of 46 patients.39.3% 
patients had malena,20.5% of children had hematemesis.3.6% had more 
than one bleeding manifestation. Children with hematemesis had a 
significantly poor outcome(p=0.000) compared to children with 
malena(p=0.52). 
  
S.no. Type of bleed No Percent 
1 g i bleed 46 41.07 
2 epistaxis 3 2.7 
3 gum bleed 3 2.7 
4 iv site 1 0.9 
5 petechiae 11 9.8 
6 purpura 6 5.4 
  
 
 
TABLE 21:CORRELATION BETWEEN THE 
COUNTS, ERYTHEMATOUS RASH AND HESS TEST 
POSITIVITY 
S.No. Platelet Count 
Freque
ncy 
Patients 
with rash 
% of total 
Hess 
test 
% of total 
1 <10,000 7 3 42.9 2 28.6 
2 11,000-20,000 17 9 52.9 5 29.4 
3 21,000-50,000 38 21 55.2 8 21.1 
4 51,000-1,00,000 50 21 42 4 8 
 TOTAL 112 54 48.21 
(p>0.05) 
19 16.96 
(p>0.05) 
 
48.2% children had a rash.Children with counts between 21000-
50000  had the highest incidence of erythematous rash.Hess test was 
positive in 16.9% of the children in the study group.Hess test positivity was 
mostly seen in children with counts between 10000- 20,000(58%).But these 
are not significant.Both rash and  Hess test are not associated significantly 
with the outcome(p>0.05) .Hess test was significantly positive in 23.9% 
children with bleeding(p=0.017). 
  
  
 
FIGURE 20:COMPARISON OF BLEEDING MANIFESTATIONS
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FIGURE 19:CORRELATION BETWEEN  PLATELET COUNT AND 
BLEEDING RISK 
 
          
The bleeding risk has been highest among children with platelet 
counts between 11,000-20,000 platelets.At counts lesser than 10,000 there 
has not been necessarily an increased % of bleeders.At higher counts,the 
percentage of bleeders is equally comparable(55.2%  at counts between 
21000-50000 and 52% at counts >50,000). So we can clearly see that there 
is poor correlation between the platelet counts and bleeding risk in the study 
group(p>0.05)        
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TABLE 22:PATIENTS WITH BLEEDING MANIFESTATION 
UNDER DIFFERENT PLATELET RANGE GROUPS AND THE 
MORTALITY 
platelet 
count 
n as 
% of 
total 
patients 
with 
bleeding 
% 
no of 
deaths 
percentage 
mortality 
mortality 
among 
bleeders in 
% 
<10,000 6.3 5 71.4 4 57.1 80 
11,000-
20,000 
15.2 15 88.2 3 17.7 20 
21,000-
50,000 
33.9 21 55.2 1 2.6 4.8 
51,000-
1,00,000 
44.6 26 52 0 0 0 
TOTAL 100 67(p=0.153) 59.8 8 7.1 11.9(p=0.097) 
 
Children with counts between 11000-20000 had the highest number 
of bleeding manifestations(88.2%)followed closely by children with counts 
less than 10,000(71.4%).Children with severe thrombocytopenia less than 
10,000  had a poor outcome.They  constituted 50% of the total deaths and 
the mortality rate was 57.1%. The mortality was higher(80%) when 
children with counts less than 10,000 developed bleeding 
manifestations.The overall mortality among bleeders is 7.1%.But none of 
these findings are statistically significant .                                                            
  
  
 
FIGURE 22:DISTRIBUTION OF PLATELET COUNTS IN STUDY 
FIGURE 23:BLEEDING MANIFESTATIONS UNDER DIFFERENT 
PLATELET RANGES AND MORTALITY AMONG BLEEDERS
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TABLE 23:COMPARISON OF THE LAB PARAMETERS 
S.NO. investigation 
total 
n=112(% 
of  n) 
dengue 
n=66(% 
of  n) 
enteric 
n=13(% 
of  n) 
leukem
ia n=5 
septicemia 
n=5(% of  
n) 
1 Leucopenia 32(28.6) 17(25.8) 5(38.5) 2(40) 1(20) 
2 Leukocytosis 29(25.9) 13(19.7) 4(30.7) 3(60) 0 
3 Pancytopenia 4(3.6) 1(1.5) 0 2(40) 0 
4 Anemia(p<0.05) 40(35.7) 15(22.7) 3(23) 5(100) 4(80) 
5 Inc esr 41(36.6) 14(21.2) 7(53.9) 4(80) 4(80) 
6 Inc urea/creat 27(24.1) 17(25.8) 1(7.7) 1(20) 2(40) 
7 Inc liver enz 33(29.5) 15(22.7) 5(38.5) 0 0 
8 Inc bilirubin 12(10.7) 2(3.03%) 1(7.7%) 0 0 
 
Anemia and an increase in the erythrocyte sedimentation rate were 
the most common hematological abnormalities associated with 
thrombocytopenia.Enteric fever children had either leucopenia or 
leukocytosis and increased liver enzymes,in higher proportion compared to 
children with Dengue.Anemia was seen in all the leukemia cases.Increase 
in the ESR, azotemia had  high association with septicemia.Children with 
anemia had a significantly poor outcome(p=0.008).The mean Hb in the 
discharged patients was 11.32gm%  compared to 8.69gm% in children who 
expired(p=0.007).The other laboratory parameters did not significantly alter 
the outcome. 
  
  
 
 
FIGURE 24: FREQUENCY OF LAB ABNORMALITIES IN THE 
STUDY GROUP 
 
FIGURE 25:COMPARISON OF  LAB ABNORMALITIES 
BETWEEN DENGUE AND ENTERIC FEVER 
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TABLE 24:COMPARISON OF PLATELET COUNTS BASED ON 
ETIOLOGY 
                        
Dengue cases have had the lowest counts.Counts have not been less 
than 20,000 in enteric fever and malaria.Even in dengue,the commonest 
platelet level is  more than 50,000.  
  
Counts 
dengue 
n=66(% 
of  n) 
enteric 
n=13(% 
of  n) 
D/E 
mixed 
n=4(%) 
malaria 
n=3(% 
of  n) 
ALL 
n=5(% 
of  n) 
Sepsis 
n=5(% 
of  n) 
<10,000 2(3) 0 0 0 1(20) 1(20) 
11000-20,000 10(15.2) 0 0 0 1(20) 0 
21000-50,000 22(33.3) 4(30.8) 3(75) 2(66.7) 2(40) 2(40) 
51000-100000 32(48.5) 9(69.2) 1(25) 1(33.3) 1(20) 2(40) 
  
 
 
TABLE 25:COMPARISON OF BLEEDING IN RELATION TO THE 
ETIOLOGY 
 
Among bleeders too,the most common etiology was Dengue 
fever.But patients with enteric fever and thrombocytopenia had higher 
incidence of  bleeding compared to even dengue cases.In fact,co infection 
with  both diseases  had the highest incidence of bleed(75%).In children 
with Dengue,counts less than 20,000  had high association with 
bleeding,while in enteric fever there was no such correlation with the 
counts for the predisposition to bleed. 
  
Counts 
patients 
with 
bleed 
dengue 
n=66 
enteric 
n=13 
D/E 
n=4 
malaria 
n=3 
ALL 
n=5 
sepsis 
n=5 
<10,000 5 2(40) 0 0 0 0 0 
11000-20,000 15 9(60) 0 0 0 1(6.67) 0 
21000-50,000 21 11(52.4) 2(9.5) 2(9.5) 1(4.8) 1(4.8) 1(4.8) 
51000-100000 26 14(53.9) 6(23.1) 1(3.9) 0 1(3.9) 2(7.8) 
Total 67 36(54.6) 8(61.5) 3(75) 1(33.3) 3(60) 3(60) 
  
 
FIGURE 26:COMPARISON OF THE PLATELET COUNTS 
BETWEEN DENGUE AND ENTERIC FEVER
FIGURE 27:COMPARISON OF  BLEEDING MANIFESTATIONS 
BETWEEN DENGUE AND ENTERIC FEVER
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FIGURE 28:DISTRIBUTION OF PLATELET COUNTS IN DENGUE 
 
 
 
 
 
 
 
 
  
FIGURE 29:DISTRIBUTION OF BLEEDING MANIFESTATIONS 
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TABLE 26:COMPARISON OF THE THREE TYPES OF DENGUE 
WITH  RELATION TO THE PLATELET COUNTS 
 
Among dengue cases,counts less than 10,000  had a 100% incidence 
of Dengue shock syndrome.Most patients with Dengue shock syndrome had 
counts between 11000-20,000(40%).Platelet counts less than 20,000 have 
thus had a high association with severe dengue. 
  
S.NO. COUNTS 
DF 
(n=36) 
DHF 
(n=21) 
DSS 
(n=9) 
1 <10,000 0 0 2(100) 
2 11000-20,000 2(20) 4(40) 4(40) 
3 21000-50,000 11(50) 8(36.4) 3(13.6) 
4 51000-100000 23(71.9) 9(28.1) 0 
  
 
 
TABLE 27:COMPARISON OF THE THREE TYPES OF DENGUE 
WITH RELATION TO BLEEDING 
 
DSS children  had a higher incidence of bleeding manifestations 
(77.8%),and the bleeding risk in DSS was high when the counts were below 
10,000.Comparatively only 11.1% of dengue fever cases had bleeding.In 
DHF too,the incidence of bleeding manifestations was high(71.4%) but 
there was no correlation with lower counts to occurrence of bleeding 
manifestations. 
  
S.NO. counts 
dengue 
with 
bleed 
DF(n=36) 
DHF(n=
21) 
DSS(n
=9) 
1 <10,000 2 0 0 2(100) 
2 11000-20,000 9 1(11.1) 4(44.4) 4(44.4) 
3 21000-50,000 11 5(45.5) 5(45.5) 1(9.1) 
4 51000-100000 14 8(57.1) 6(42.9) 0 
 Total 36 14(11.1) 15(71.4) 7(77.8) 
  
 
 
FIGURE 30: COMPARISON OF  PLATELET COUNTS IN DENGUE 
 
FIGURE 31:COMPARISON OF  THE INCIDENCE OF BLEEDING 
MANIFESTATIONS IN DENGUE
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TABLE 28:COMPARISON OF MEAN HEMATOLOGICAL 
VALUES BASED ON ETIOLOGY 
s.no. Diagnosis 
Mean 
Hb(gm%) 
Mean PCV(%) 
Mean platelet 
count 
1 DF 11.93 37.74 60666 
2 DHF 11.98 39.77 46714 
3 DSS 11.21 38.04 18000 
4 enteric 12.15 35.58 62076 
5 ent/den co inf 11.38 35.55 41500 
6 malaria 11.03 34.47 46333 
7 leukemia 4.27 13.36 35600 
8 septicemia 9.96 30.56 50800 
 Total(n=112) 11.13 35.99(p=0.016) 48250 
 
The mean hemoglobin value in the study group is 11.13gm%.The 
mean hematocrit value is 35.99%,and the outcome is significantly poor 
among children with hematocrit below the mean(p<0.05) probably 
indicative of the mortality risk associated with bleeding .The mean platelet 
count is 48,250/µL.Hematocrit was highest among DHF(39.77) cases with 
slight decrease in DSS cases(38.04).The mean platelet count was 
significantly lower in DSS cases(18,000/µL).Anemia with 
thrombocytopenia was common in leukemia and septicemia(4.27 gm% and 
9.96gm% respectively).  
  
  
 
 
TABLE 29:COMPARISON OF THE  DENGUE SEROPOSITIVITY 
S.NO. Dengue panel 
DF 
(n=36) 
DHF 
(n=21) 
DSS 
(n=9) 
Enteric/deng 
co inf(n=4) 
1 IgM POSITIVE 8(22.2) 4(19) 7(77.8) 0 
2 IgG  rise in titre 5(13.9) 0 0 1(25) 
3 NS1 POSITIVE 5(13.9) 0 0 0 
4 IgM/IgG POSITIVE 8(22.2) 10(47.60) 1(11.1) 3(75) 
5 IgM/NS1 
POSITIVE 
7(19.4) 3(14.3) 0 0 
6 TRIPLE POSITIVE 3(8.3) 4(19) 1(11.1) 0 
p>0.05 
Dengue fever cases had more monopositivity(50% cases) and 
IgM/NS1 positivity compared to DHF and DSS cases,indicating that they 
were most probably primary infection.DHF cases had a higher proportion of 
IgM/IgG and triple dengue panel(NS1,IgM,IgG) test positivity,suggesting 
that they were more of secondary infections.In contrast,DSS cases had high 
frequency of IgM monopositivity. 
However,seropositivity in dengue is not significantly related to the 
outcome.(all the three investigations had p values more than 0.05). 
  
  
 
FIGURE 32: COMPARISON OF MEAN HEMATOLOGICAL 
FIGURE 33:GRAPH COMPARING SEROPOSITIVITY IN DENGUE
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TABLE 30: COMPARISON OF RADIOLOGICAL 
ABNORMALITIES 
Features 
TOTAL 
(n=112) 
(%) 
p value 
DF 
(n=36) 
DHF 
(n=21) 
DSS 
(n=9) 
Enteric 
(n=13) 
X ray eff/pneumonia 15(13.4) 0.002 1(6.6) 4(26.6) 1(6.6) 2(13.3) 
Gall bladder edema 31(27.7) 0.001 0 11(52.4) 4(44.4) 8(61.5) 
Pleural effusion 29(25.9) 0.008 0 15(71.4) 5(55.5) 4(30.7) 
Ascites 18(16.1) 0.062 0 8(38.1) 3(33.3) 3(23.1) 
Hepatomegaly 45(40.2) 0.338 10(27.8) 9(42.9) 3(33.3) 10(76.9) 
Splenomegaly 27(24.1) 0.397 6(16.7) 5(23.8) 0 4(30.7) 
Abnormal X ray findings had a significant association with 
mortality(p<0.05). Ultrasound abdomen was a very useful radiological tool 
among the study population.It was able to pick up features of polyserositis 
with high sensitivity in both DHF  and  DSS.But the findings were not 
specific for dengue alone.Even in enteric fever,pericholecystic edema with 
gall bladder thickening was a consistent feature(61.5%).Hepatomegaly was 
seen in more than 75%  of both enteric fever and enteric/dengue co 
infection cases.Gall bladder wall edema and pleural effusion in Ultrasound 
were seen in high frequency in children with bleeding.This is statistically 
significant(p<0.05). 
  
  
 
FIGURE 34:FREQUENCY OF ULTRASOUND FINDINGS IN 
CHILDREN WITH THROMBOCYTOPENIA
FIGURE 35: COMPARISON
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TRANSFUSION REQUIREMENTS 
Standard protocols were followed in transfusing blood products to 
the children.Majority received packed cells and platelets,while lesser 
number of patients were transfused whole blood and colloids.The cause for 
most transfusions was severe shock with bleeding manifestations,while few 
children were transfused prophylactically in view of drastically decreasing 
counts.                                                                                
TABLE 31:PROFILE OF TRANSFUSED CHILDREN 
Parameter no of children % 
Children who received blood products 20 17.9% 
Children who had bleeding 17 85%(p<0.05) 
Mortality among transfused patients 6 30% (p<0.05) 
Children with associated anemia 15 75%(p=0.001) 
Lowest count for which transfused 7000 
Mean transfusion volume requirement  43.75 ml/kg/patient 
Mean  count of transfused patients 24,000/L(p=0.038) 
Major diagnosis for which transfused DSS 
% of DSS patients transfused 77.8% 
 
 
 
 
  
 
 
Anemic patients with thrombocytopenia had significantly increased 
need for transfusions(p<0.05).The mean Hb of transfused  patients was 
9.65gm% compared to 11.46gm%  in non  transfused patients(p=0.006). 
3 patients who were transfused had counts less than 10,000/µL.9 
children had counts between11,000-20,000/µl,7 between 21,000-50,000/µl 
while one patient with a count of 78000 was transfused.72.9% patients who 
had low platelet counts were not given any transfusion and  improved.This 
is statistically significant(p=0.007).Also patients with low admission 
platelet counts and also rapid drop in counts required more transfusions 
(p<0.05). 
25.4% of patients with bleeding manifestations were 
transfused(p<0.05). Among the bleeding manifestations,children with 
hematemesis and malena had a significantly increased need for 
transfusions(p<0.05).  
There was  also statistically significant association between need for 
transfusion and mortality(p<0.05).All the poor predictors of mortality also 
had significant association  with the need for transfusions.Hence,it can be 
implied that transfusions have not significantly altered the outcome. 
           
 
 
  
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
  
 
 
6. DISCUSSION 
As discussed in the literature,thrombocytopenia,being associated 
with bleeding manifestations is now considered an independent parameter 
predicting outcome in the paediatric intensive care unit64. Here,critical 
analysis of the observations of our study is performed, comparing it with 
other Indian and foreign studies. 
AGE WISE INCIDENCE: 
Analysis of our study shows the highest incidence of 
thrombocytopenia in the 6-10 years age group,with a mean age of 6.56 
years.Ali jan et al59 found higher incidence in the 1-5 yrs age group,while 
Sachdev et al60 reported  two  and a half years as the median age.The 
present  study is comparable with Shahanaz et al,Lahore which reported 4-7 
years as the commonest age group affected.  
SEX WISE DISTRIBUTION: 
There is no particular sex predilection for thrombocytopenia.The 
male female ratio in the present study was 0.89:1 while Sachdev et al60  
reported  1.76:1 and Ali jan et al59 reported 1.9:1.Such wide variations 
could be due to socio cultural differences. 
INCIDENCE: 
The incidence of thrombocytopenia has been quoted to vary from 13-
58% in various studies2.The present  study has shown 15.95% 
incidence,which is comparable to other studies;Sachdev et al60 showing 
  
 
 
23.2% and 22% in a neonatal  ICU65.A study done in St.louis 
university,USA by Krishnan et al also showed a very similar incidence of 
17.3%. 
PLATELET TRENDS: 
The  present study had significantly less  number of children with 
counts less than 10,000 compared  to Sachdev et al60(20%).But it is 
comparable in the other platelet ranges(15.2% between 11,000-20,000) to 
studies by Chandrakanta et al66(13.7%) and Mittal et al62,University College 
of Medical Sciences,Delhi(14.4%). 
TABLE 32:COMPARISON OF PLATELET TRENDS BETWEEN 
VARIOUS STUDIES 
S.NO. platelet count 
Present 
study % 
sachdev 
et al60  % 
Chandrak
anta et al66 
Mittal et 
al61 
1 <10,000 6.3 20   
2 11,000-20,000 15.2 28 13.7 14.4 
3 21,000-50,000 33.9 42.5 29.9 56.3 
4 51,000-1,00,000 44.6 8.6 17.4 29.3 
Children with counts less than 10,000 had the worst outcome(57.1% 
mortality).Drop in platelet count >27% was significantly associated with 
mortality reported by Sachdev et al,which is comparable to the findings of 
the present study. 
  
 
 
FIGURE 36: COMPARISON OF PLATELET COUNT TRENDS 
BETWEEN THE VARIOUS STUDIES 
 
MORTALITY: 
Mortality in the present  study was 7.1% with DSS contributing to 
50% of the deaths.Krishnan et al64 reported 17.1% mortality,while Sachdev 
et al60  reported a mortality of 10.9%.  Mortality was highest among 
infants(45.5%) and younger chidren(<3 years).This is consistent with the 
observation by WHO67  that infants are prone for severe forms of the 
disease. The WHO observed case fatality rate in India is 3-5%. 
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ETIOLOGY COMPARISON: 
The commonest etiology for newly diagnosed thrombocytopenia 
among children in the present  study was Dengue(58.8%).Ali jan et al59 
reported ITP as the commonest diagnosis(32%). 
TABLE 33:COMPARISON OF ETIOLOGY BETWEEN  STUDIES 
S.no. Etiology 
Nair PS et al, St. 
Stephen's Hospital, 
, 200368(n=109) 
Present 
study(n=112) 
1 Dengue 13.8% 58.8% 
2 Enteric fever 14.7% 11.6% 
3 Septicemia 26.65% 4.5% 
4 Malaria 9.2% 2.7% 
5  malignancy 3.7% 4.5% 
6 Others/unknown 18.3% 14.2% 
The variation in the etiological data could be due to the differences in 
disease prevalence between the northern and southern parts of the 
country.Also,the study was done during the dengue season,explaining the 
higher percentage of dengue cases. 
COMPARISON OF  DENGUE DATA: 
Since dengue was the commonest diagnosis in the present  study 
population with a good sample size(66cases),a detailed analysis of dengue 
was performed.Dengue fever with or without hemorrhage(DF) was most 
common(32.1%) . DSS comprised only 8% of cases with  
 
  
 
 
thrombocytopenia, but had the highest mortality rate of 44.4%.This 
could be attributed to the high baseline microvascular permeability in 
children69. 
Abdominal pain and vomiting were present in half to two-third of the 
patients in the present study which is consistent with other studies.Similar 
to other studies,platelet counts had no correlation to the bleeding 
manifestations in dengue.Majority of bleeding in the present study was 
observed in patients with counts more than 50,000.This confirms further 
that bleed in dengue is due to aberrant immunity and cross reactivity rather 
than a effect of the decrease in number.Indiscriminate  platelet transfusions 
thus need to be avoided. 
DSS cases with counts less than 10,000 have had a higher incidence 
of bleeding manifestations and mortality.Intensive monitoring and judicious 
fluid management may be needed to improve the outcome in such children. 
Gomber et al70 defines 36.3% as the cut-off hematocrit for DHF.In 
the present study,the mean hematocrit among  dengue patients was well 
above this cutoff,indicating high predisposition for development of severe 
dengue in the study group.Also,the hematocrit values are significantly 
associated with mortality.Unlike previous studies,the incidence of co 
infections in the present  study was low(5.7%).But the children with 
dengue/enteric co infection had abdominal tenderness in a higher 
proportion.The mortality rate among dengue patients as a whole was 
low(4/66=6.06%) . 
  
 
 
Erythematous rash with flushing was very commonly observed  in 
children with dengue in the present study(70.4%).This is inspite of the dark 
complexion in our children.Hence,there must be a high index of suspicion 
regarding dengue  whenever a child presents with fever and rash in dengue 
endemic area.The present study showed a  higher incidence of bleeding 
manifestations compared to previous studies but less number of severe 
forms of the disease(DHF and DSS).This could probably be due to the 
serotype of the dengue virus that is circulating in and around Tirunelveli, 
and also the environmental factors.Serotyping could not be done in the 
present study,which could be a prospective area for further studies. 
TABLE34:COMPARISON OF STUDIES ON DENGUE 
 
Author Chandrakanta et al66 Mittal et al61 Present study 
Place Lucknow Delhi Tirunelveli 
DF/DHF/DSS 31.2% DHF 8/51/42 54.6/31.8/13.6 
Fever 100% 100% 100% 
Abdominal pain 25% 71% 53% 
Vomiting 41.2% - 63.6% 
Bleeding 38.8% 48.8% 54.6% 
Rash 37.5% 26.6% 70.4% 
Hypotension 10% 43% 13.6% 
Hepatomegaly 62.5% 31.1% 33.3% 
  
 
 
Author Chandrakanta et al66 Mittal et al61 Present study 
Splenomegaly 60% 27% 16.7% 
Leucopenia - 17.7% 25.8% 
Mean hct 26.8% 36.1% 38.5% 
Mean hb 9.8gm 11.5gm 11.7gm 
Plt <20,000 13.7% 14.4% 18.2% 
20-50,000 29.9% 56.3% 33.3% 
>50,000  17.4% 29.3% 48.5% 
Deranged LFT 66.7% 48% 22.7% 
Pleural effusion - 6% 30.3% 
Ascites/gb edema - 13% 22.7% 
 
HESS TEST: 
Hess test was positive in 16.9% of the children in the study 
group.Hess test positivity was mostly seen in children with counts between 
10000- 20,000(58%).85.7% positivity was shown by Shigeki Hanafusa 
(Japan) et al71,23.7%  by Narayanan et al  and 52% by Kalyanarooj et al 
(Indonesia).The low percentage in the present study(similar to another 
Indian study Narayanan et al)compared to foreign studies may be due to the 
difference in skin complexion and capillary fragility in Indian children.Hess 
test in the present study had significant association with bleeding. 
 
  
 
 
SEROLOGICAL INVESTIGATIONS IN DENGUE: 
The present study showed 63.9% NS1 positivity,84.8% IgM 
positivity and 48.5% showed fourfold rise of IgG.Comparatively a study in 
Kuala lumpur Malaysia by Kassim et al72 showed 32.2% NS1 
positivity,40.9% IgM and 36.1% IgG positivity.All three investigations 
were very useful in identifying both primary and secondary dengue 
infection.Triple positivity was seen in 36% of the cases.DHF had features 
suggestive of secondary infection. 
PREDICTORS OF MORTALITY: 
Altered sensorium,tachycardia,tachypnea,shock(all  having 100% 
association with death),requirement of inotrope support(87.5%),mechanical 
ventilation(70%) ,seizures,malnutrition were all significantly associated 
with increased mortality.Requirement of mechanical ventilation in Sachdev 
et al59 was 23.9% whereas in the present  study,it was 6.3%.The incidence 
of shock was 17.3% in Sachdev et al while in the present study it was 
16.1%. 
In the study group,cases with seizures and thrombocytopenia had 
high mortality.This could probably be because of intracranial bleed induced 
by the thrombocytopenia.Abdominal distension  and pedal edema were 
significantly seen in increased frequency in children who expired.This 
could be probably because of plasma leakage associated with 
thrombocytopenia in dengue,and probable unidentified compartment 
  
 
 
syndrome.Hematemesis was also seen in significantly  increased frequency 
in the expired children.Children with anemia also had a significantly poor 
outcome probably because they could not tolerate the bleeding. 
BLEEDING MANIFESTATIONS: 
Bleeding manifestations were seen in a total of 67 patients(59.8%) in 
the present study compared to 19.5% in Sachdev et al.GI bleed was the 
commonest bleeding manifestation associated with thrombocytopenia,seen 
in total of 46 patients. There was significant association between vomiting 
,abdominal distension and bleeding .Children with counts between 11000-
20000 had the highest number of bleeding manifestations(88.2%)followed 
closely by children with counts less than 10,000(71.4%).The overall 
mortality among bleeders is 7.1%.Bleeders with counts less than 10,000 had 
87.5% mortality.But bleeding in thrombocytopenia was not significantly 
related to the platelet count or to the  mortality. 
  
  
 
 
TABLE 35:COMPARISON OF BLEEDING MANIFESTATIONS 
BETWEEN VARIOUS STUDIES 
S.NO. Study Present study Nair et al68 Ali jan et al59 
1 GI bleed 41.07% 9.2% 6% 
2 Epistaxis 2.7% 6.4% 34% 
3 Gum bleed 2.7% 5.5% 28% 
4 Petechiae/purpura 9.8% 9.2% 32% 
5 Others 0.9% 3.7% 10% 
 
The wide variations observed are due to the different study 
populations.Ali jan et al59 had more ITP cases.In ITP,milder mucosal bleeds 
are more common.Again,petechiae and purpura are more likely to be 
missed in the Indian population  because of the dark complexion in our 
children. 
TRANSFUSION REQUIREMENTS: 
Inspite of several studies,evidence based guidelines for transfusions 
in children with thrombocytopenia are ambiguous.As discussed in the 
literature,in most clinical situations,the treating physician is made to act on 
his own discretion rather than strictly follow guidelines. 
17.9% children in the present  study required transfusions.They 
received 43.75 ml/kg/patient.In comparison,21.9% patients were transfused 
in the study by Sachdev et al. and transfusions were reported to be 
  
 
 
significantly associated with mortality.Most of the patients transfused in our 
study were DSS patients(77.8%).The mean platelet count of transfused 
patients was 24,000.Yet  80% mortality was seen in the transfused 
patients,which was also statistically significant.Patients with low platelet 
counts and bleeding manifestations also did not show statistically 
significant improvements in comparison to non transfused patients. 
Hence, the role of prophylactic platelet transfusions is to be 
questioned until uniform guidelines are established.WHO advises that 
platelet transfusions are to be avoided in dengue.The only clinical situation 
where platelet transfusion is needed in dengue is when the counts are less 
than 10,000. 
The limitations in our study have already been listed.Considering that 
our study was a small scale study done in an area with low malaria 
endemicity(a disease very commonly associated with 
thrombocytopenia)and with serological studies for viral markers not being 
done ,the observations of  the present study are definitely subject to 
confounding.There were also very few studies on paediatric 
thrombocytopenia for comparison. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
7. CONCLUSION 
 Thrombocytopenia is common in the paediatric age 
group.Approximately,one in every six hospital admissions develop 
thrombocytopenia. 
 Children less than 3 years with thrombocytopenia have a poor 
prognosis.Therefore,they need intensive monitoring. 
 Dengue fever is the leading cause for newly detected thrombocytopenia 
in this study. 
 Dengue shock syndrome is the leading cause of mortality in the present 
study.Platelet counts less than 10,000 and bleeding in children with 
shock have the worst outcome.Judicious fluid management strictly 
following the WHO guidelines along with intensive clinical monitoring 
can go a long way in reducing mortality in this group of patients. 
 Early identification of thrombocytopenia at the primary and secondary 
levels with proper referral do affect the outcome.Hence the need to 
sensitise those clinicians at these levels and strengthen these services. 
 Erythematous rash with flushing is a sensitive clinical sign to identify at 
risk children.It needs to be looked for in children in endemic areas 
during seasonal outbreaks. 
 Altered sensorium, tachycardia, tachypnea, shock, seizures, 
malnutrition, need for inotrope support and for  mechanical ventilation 
are all predictors of mortality.Intensive care facilities at tertiary level 
  
 
 
needs to be strengthened further in order to reduce mortality in these 
patients. 
 Hematemesis and abdominal distension are significantly associated with 
mortality.They are warning signs and are to be given due importance as 
third space blood loss can go unnoticed and produce compartment 
syndrome. 
 Intracranial bleed needs to be managed aggressively and 
appropriately.Occurence of seizures in septicemia children with 
thrombocytopenia has had a 100% mortality. 
 Platelet counts less than 20,000 have been frequently associated with 
bleeding.Counts less than 10,000 had higher mortality and association 
with DHF and DSS.Serial platelet counts are good predictors of disease 
progression in these patients,because of the dynamic nature of the 
platelet count. 
 Hess test and hematocrit done early are sensitive in picking up cases 
prone for severe dengue and must  be done in all cases.Hess test 
especially is sensitive in picking up children prone for bleeding 
manifestations. 
 Likewise,Chest X ray and Ultrasound abdomen are very sensitive in 
picking up polyserositis in DHF which must be done  in all 
cases.Clinicians can be easily trained in performing an ultrasound and it 
is a comparatively cost effective diagnostic tool,which may be made 
  
 
 
mandatory in all secondary centres. 
 Children with septicemia had increased ESR and azotemia associated 
with thrombocytopenia.Since the number of septicemia cases was 
small,this association needs to be elaborated with larger studies. 
 IgM dengue ELISA is sensitive in identifying dengue.Along with NS1 
and IgG,it is useful in categorizing primary and secondary infections and 
thus identify predisposition to severe dengue. 
 Transfusion of blood products have not significantly altered the outcome 
to a great extent.Also most thrombocytopenia in the present  study was 
transient and the counts recovered in due time with treatment of the 
primary pathology.Therefore,guidelines need to be followed while 
transfusing.It is prudent to treat the clinical presentation in the patient 
rather than treat the platelet numbers.There is no role for prophylactic 
transfusions,as platelet counts do not correlate with bleeding. 
 Awareness on dengue is poor among the rural population.People have to 
be sensitized about the signs and symptoms of the disease and the 
importance of mosquito eradication.Awareness campaigns need to be 
stepped up. 
 As thrombocytopenia is  so common and has a definite bearing on 
prognosis  in the intensive care setting,it needs to be studied 
further.With the paucity of studies worldwide on paediatric 
thrombocytopenia, studies are required with larger number of patients in 
  
 
 
the paediatric age group to further consolidate the findings of the present 
study. 
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1. PROFORMA FOR THROMBOCYTOPENIA 
NAME:                                                IP NO:                    AGE/SEX: 
ADDRESS:                                                                        MOBILE NO: 
 
DOA:                                                            ADMISSION WT: 
DOD:                                                            DISCHARGE WT: 
FATHERS NAME:                                         MOTHERS NAME: 
OCCUPATION:                                              INCOME: 
CONSANGUINITY:                                     SIBLINGS: 
FAMILY HISTORY; 
ILLNESS STARTED ON:                          DAY OF PRES: 
PRE HOSPITAL TREATMENT:DRUGS: 
                                                 IV FLUIDS: 
                          GENERAL CONDITION: 
                                       TRANSFUSIONS: 
      DIAGNOSIS: 
                           DAY OF ILLNESS PRES: 
    PVT/GOVT SET UP: 
CHIEF PRESENTING COMPLAINT WITH DURATION: 
FEVER :                         TYPE:                         PERIODICITY: 
CHILLS/RIGORS:                   SWEATING EPISODES: 
RELIEF WITH ANTIPYRETICS: 
COUGH:                                                       
VOMITTING:                                            
HEMATEMESIS: 
MALENA: 
RASH: 
HEMATURIA: 
LOOSE STOOLS: 
  
 
 
                                                                                                                                                                      
ABD PAIN: 
ALOC/SEIZURES: 
BONE PAINS: 
BREATHLESSNESS: 
REFUSAL OF FEEDS: 
LOW/LOA: 
IRRITABLE CRY: 
FEATURES OF EDEMA: 
ANTECEDENT  ILLNESS IN THE PAST MONTH: 
OTHERS:(OTHER COMPLAINTS/COMORBIDITIES) 
DRUG INTAKE/DAYS: 
PAST HISTORY: 
H/O BLOOD TRANSFUSION: 
DEV HISTORY:                               IMM STATUS: 
GENERAL EXAMINATION AT PRES: 
GC  AVPU  TACHYPNEIC  
TEMP  HR  RR  
PULSES  PALLOR  ICTERUS  
LYMPH 
NODES 
 BP  TOURNIQUET 
TEST 
 
FACIAL 
PUFFINESS 
 PEDAL 
EDEMA 
 CYANOSIS  
PERIPHERIES  WEIGHT  WT PERCENT  
HEIGHT  HT PERCENT  AIRWAY  
SP O2  PUPILS  FUNDUS  
COLOUR  GCS  BONE 
TENDERNESS 
 
OTHER FINIDNGS IF ANY: 
CVS: 
RS: 
P/A(LIVER SPAN): 
CNS: 
DESCRIPTION OF RASH: 
PALPABLE/NON PALPABLE:                       SIZE: 
COLOUR:                BLANCHING/REFILL: 
  
 
 
                                                                                                                                                                      
 
INVESTIGATIONS: 
INV  DAT
E 
REPOR
T        
DAT
E 
REPOR
T 
DAT
E 
REPOR
T 
DAT
E 
REPOR
T 
TC         
DC         
ESR         
HB         
PCV         
PT COUNT            
BLEEDING 
MANIFESTATIO
N 
        
SUGAR         
AMYLASE         
UREA         
CREATININE         
NA         
POT         
BILIRUBIN         
SGOT         
SGPT         
ALP         
ALBUMIN         
GLOBULIN         
A/G RATIO         
URINE 
A 
S 
D 
        
URINE C/S: 
BLOOD C/S: 
IgM DENGUE ELISA: 
PERIPHERAL SMEAR 
RETIC COUNT: 
WIDAL: 
BT;                                                             CT: 
PT: 
APTT: 
HIV ELISA: 
ANA: 
CXR: 
USG ABDOMEN: 
  
 
 
                                                                                                                                                                      
BONE MARROW: 
OTHERS IF ANY: 
INITIAL TREATMENT: 
IVF:                    ABC:                            INOTROPES: 
COURSE OF ILLNESS: 
 
TRANSFUSIONS WITH DATE:          BLD GP: 
PRODUCT DT    
     
     
     
 
STEROIDS:                                  DATE STARTED: 
DATE        
FLUID        
INPUT        
OUTPUT        
TEMP               
SPIKE: 
COMPLICATIONS: 
FINAL DIAGNOSIS: 
FOLLOW UP GC 
PLATELET LEVEL: 
REMARKS: 
QUESTIONNAIRE: 
1.HAVE YOU HEARD THE WORD “DENGUE”? 
2.TELL THE SIGNS AND SYMPTOMS OF THE DISEASE 
3.HOW IS THE DISEASE TRANSMITTED? 
 
 
 
 
 
 
 
  
 
 
                                                                                                                                                                      
  2. ABBREVIATIONS USED IN THE TEXT 
 VWF-VON WILLEBRAND FACTOR                                       
  SLE-SYSTEMIC LUPUS ERYTHEMATOSUS                          
 ALL-ACUTE LYMHOBLASTIC LEUKEMIA                              
 PT-PROTHROMBIN TIME                                                       
  APTT –ACTIVATED PARTIAL THROMBOPLASTIN TIME     
 DENV-DENGUE VIRUS                                         
 HCT-HAEMATOCRIT                                                               
 ADP-ADENOSINE DIPHOSPHATE 
 ATP-ADENOSINE TRIPHOSPHATE 
 HIV-HUMAN IMMUNODEFICIENCY VIRUS 
 ITP-IDIOPATHIC THROMBOCYTOPENIC PURPURA 
 EBV-EBSTEIN BARR VIRUS 
 CMV-CYTOMEGALOVIRUS 
 HCV- HEPATITIS C VIRUS 
 HIT-HEPARIN INDUCED THROMBOCYTOPENIA 
 TTP-THROMBOTIC THROMBOCYTOPENIC PURPURA 
 HUS-HEMOLYTIC UREMIC SYNDROME 
 NS-NON STRUCTURAL PROTEIN 
 EDTA-ETHYLENE DI AMINE TETRA ACETIC ACID 
 WHO-WORLD HEALTH ORGANISATION 
 DF-DENGUE FEVER 
 DHF-DENGUE HEMORRHAGIC FEVER 
 DIVC-DISSEMINATED INTRAVASCULAR COAGULATION 
 PUO-PYREXIA OF UNKNOWN ORIGIN 
 ICU-INTENSIVE CARE UNIT                                                  
 ESR-ERYTHROCYTE SEDIMENTATION RATE 
  
 
 
                                                                                                                                                                      
 ICB/H-INTACRANIAL BLEED/HEMORRHAGE 
 MPV-MEAN PLATELET VOLUME 
 RBC-RED BLOOD CELL 
 DSS-DENGUE SHOCK SYNDROME                                        
 SD-STANDARD DEVIATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
MASTER CHART 
 
 
 
 
 
S.NO   IP NO     AGE SEX WT WT FOR AGE PRE HOSP ADEQ  STAY ADM FEVER TOTAL FEVER COUGH VOMITING 
1 59151 9 F 20 II PVT I 3 4 10 N Y 
2 58928 5 M 14 I GH A 5 4 4 Y Y 
3 59387 3 M 10 I GH A 7 7 12 Y Y 
4 60598 3 M 12 N SELF NA 4 6 7 N Y 
5 59915 8 F 20 N GH I 7 3 7 Y Y 
6 59983 2 M 10 N PVT A 6 2 5 N N 
7 60194 7 M 20 N PVT NA 8 4 5 Y Y 
8 60318 12 M 23 III PVT A 5 5 7 Y N 
9 61450 11 M 35 N GH A 5 8 9 N Y 
10 61188 2 F 6.5 III GH A 3 7 8 N Y 
11 61225 7 M 14 II SELF NA 5 7 5 Y Y 
12 61183 12 F 24 III SELF NA 12 4 5 N N 
13 232 8 F 22 N SELF NA 7 3 5 N Y 
14 384 1 F 8.5 N GH A 7 10 10 Y N 
15 507 5 M 18 N PVT A 6 7 7 Y Y 
16 681 10 M 30 N PVT I 4 7 7 N Y 
17 509 3 F 12 N PVT A 4 4 5 N Y 
18 944 7 F 17 I GH A 4 7 9 N Y 
19 1384 10 M 23 I GH A 6 4 4 Y Y 
20 1651 9 M 20 II PVT A 4 7 7 N N 
21 1428 5 M 12 II PVT I 5 5 5 N N 
22 1419 9 F 15 III PVT I 5 4 4 N N 
23 1459 4 M 11 I PVT A 6 5 9 Y N 
24 1489 8 M 25 N SELF NA 4 2 3 N Y 
25 1913 7 F 19 N GH A 4 2 6 Y Y 
26 1904 10 F 22 I GH A 5 5 6 N Y 
27 1916 2 M 12 N GH A 4 6 8 N N 
28 2782 9 M 20 II PVT A 7 2 4 Y N 
S.NO   IP NO     AGE SEX WT WT FOR AGE PRE HOSP ADEQ  STAY ADM FEVER TOTAL FEVER COUGH VOMITING 
29 3967 7 F 16 I GH A 4 5 5 N N 
30 3574 7 F 20 N PVT I 5 7 10 Y Y 
31 4087 3 M 10 I PVT I 4 7 8 N N 
32 3687 5 M 13 I GH A 4 5 5 N Y 
33 3822 9 F 20 II PHC I 6 7 9 N Y 
34 3842 10 M 30 N GH A 6 7 8 N N 
35 3829 2 M 8 II SELF NA 7 5 8 N N 
36 4525 10 M 24 I PVT A 3 5 5 N N 
37 4265 5 F 14 I GH I 4 3 3 N Y 
38 4714 10 M 20 II GH I 5 3 6 Y Y 
39 4740 8 M 18 I PVT A 5 7 7 N Y 
40 5201 7 F 14 II PHC A 4 4 5 Y Y 
41 4882 12 M 23 III SELF NA 8 4 6 Y Y 
42 5228 8 F 17 I PVT A 2 2 4 Y Y 
43 5575 8 F 18 I PVT A 4 2 2 N N 
44 6109 4 M 18 N PVT A 5 3 4 N N 
45 6557 4 M 12 II SELF NA 11 7 9 Y Y 
46 6454 8 M 18 I GH A 5 5 6 N N 
47 6462 9 M 25 N SELF NA 4 4 6 N N 
48 6411 10 M 25 I GH A 10 3 8 N Y 
49 2767 9m F 8 N PVT A 12 4 10 N Y 
50 4246 6 F 15 I SELF NA 3 5 5 N Y 
51 2377 6m F 5.5 N PVT A 8 3 6 Y Y 
52 588 3 F 12 N PVT A 8 6 6 Y Y 
53 1646 9 F 16.5 III PVT I 4 5 5 Y Y 
54 60099 12 F 24 III GH I 4 5 5 N N 
55 960 8 M 18 I GH I 5 1 4 N Y 
56 4053 12 F 32 N GH I 4 4 5 N Y 
S.NO   IP NO     AGE SEX WT WT FOR AGE PRE HOSP ADEQ  STAY ADM FEVER TOTAL FEVER COUGH VOMITING 
57 5075 3 M 12 N PVT A 10 4 10 Y Y 
58 3233 7 F 18 N PVT A 3 7 7 N Y 
59 5186 9 M 21 II GH I 5 5 6 N N 
60 4673 5 M 15 I GH A 8 3 7 N Y 
61 179 8 M 21 N GH A 8 7 9 Y Y 
62 60277 12 M 25 II PVT A 4 4 4 N N 
63 5790 8m F 7 N PVT A 1 5 6 N N 
64 1290 2 F 10 N PVT A 2 3 5 N N 
65 60813 1 M 8 N PVT A 7 5 7 N Y 
66 1927 6 F 18 N PVT A 4 15 18 Y Y 
67 6690 7 M 17 I SELF NA 12 3 8 Y Y 
68 60157 3 F 11 N PVT I 5 5 7 N Y 
69 59921 8 F 16 II SELF NA 6 3 8 N Y 
70 588 3 F 12 N PVT A 6 6 6 N Y 
71 869 4 M 16 N GH A 5 7 10 N Y 
72 1785 12 M 25 III GH A 9 5 5 Y N 
73 2063 4 F 12 II PVT A 5 5 6 N Y 
74 5634 7 M 23 N SELF NA 6 5 5 Y Y 
75 876 11 F 28 I SELF NA 9 3 12 N Y 
76 2672 11 M 24 II PHC I 5 10 12 N Y 
77 4105 7 F 24 N PVT A 5 5 7 N Y 
78 59494 5 M 16 N SELF NA 4 15 16 Y Y 
79 5442 11 F 28 I PVT I 7 9 12 N N 
80 5106 10 F 25 I PVT I 5 15 17 N Y 
81 5807 10 M 20 II SELF NA 15 5 12 Y Y 
82 60712 2 F 10 N PVT I 4 15 15 Y Y 
83 60446 6 M 10 IV SELF NA 8 15 20 N N 
84 59383 7m M 6 N GH NA 7 10 14 Y Y 
S.NO   IP NO     AGE SEX WT WT FOR AGE PRE HOSP ADEQ  STAY ADM FEVER TOTAL FEVER COUGH VOMITING 
85 59413 1 M 6 II GH A 25 7 15 Y Y 
86 682 10m F 7.3 N PVT I 6 5 5 Y N 
87 2011 2m F 3 N SELF NA 2 4 6 Y Y 
88 72 2m F 3.5 N GH A 2 5 6 Y Y 
89 59811 8 F 14 III PVT A 5 5 7 N Y 
90 4700 7 F 15 II GH A 4 5 6 N Y 
91 6821 5 F 18 N PVT A 8 4 6 Y N 
92 60900 12 F 25 II PVT A 8 10 11 N Y 
93 1490 6 F 12 II SELF NA 2 14 14 N N 
94 4163 5 F 13 I PVT A 7 7 8 N Y 
95 14369 10 F 26 N SELF NA 2 10 12 Y N 
96 20573 9 F 16.5 III SELF NA 8 8 15 N N 
97 6965 3 F 13 N GH A 10 AFEB AFEB N N 
98 15117 10 F 18 III SELF NA 10 AFEB AFEB Y N 
99 22862 10 F 27 N SELF NA 1 AFEB AFEB N Y 
100 13649 12 M 28 I PVT A 8 AFEB AFEB N Y 
101 4745 8 F 17 II PVT I 5 4 4 Y Y 
102 5047 5m M 5 N PVT A 2 10 12 N N 
103 296 6 F 13 II SELF NA 3 5 6 N N 
104 576 5 M 13 I PVT I 20 2 15 N Y 
105 4877 12 F 20 III SELF NA 6 4 6 Y N 
106 4622 7 M 23 N SELF NA 15 10 10 Y N 
107 5786 3 F 10 N SELF NA 9 AFEB AFEB N N 
108 2271 9 F 25 N PVT I 6 5 6 Y Y 
109 59752 12 M 26 II SELF NA 12 2 7 N Y 
110 61457 5 F 15 N GH A 9 4 8 N Y 
111 2244 6 F 15 I GH A 7 7 8 Y Y 
112 5588 2 M 15 N GH A 6 4 6 N Y 
S.NO MYALGIA ABD PAIN TEND  DIST OLIGURIA PUFF FACE PEDAL EDEMA HEMATEMESIS MALENA BLEEDING HESS TEST 
1 Y Y Y N N N N N N N N 
2 N Y N N N P N N Y GI P 
3 Y N N N Y N N N N N N 
4 N N N N N N N N N PURPURA P 
5 Y N N N N P N N N N N 
6 Y N N N N N N N N N N 
7 Y N N Y N N N N N PETECHIAE N 
8 N Y N N N N N N N N N 
9 Y Y N N N N N N Y GI N 
10 N Y N Y N P N N Y GI N 
11 Y N N N Y P N N N N N 
12 Y N N N N N N N Y GI N 
13 N N N N N N N N N N N 
14 Y N N Y N N N N N N N 
15 Y Y N Y Y P N N N N N 
16 N Y Y Y N P P N Y GI P 
17 N Y N Y N P N N N PETECHIAE N 
18 N N N N N P N N N N N 
19 Y Y N N N N N N Y GI P 
20 Y Y N N N N N N N N N 
21 Y Y Y N N N N N N N N 
22 Y Y Y N N P N N N N P 
23 N Y Y N Y P N N N N N 
24 Y Y Y N N N N N N N N 
25 N N N N N N N N N N N 
26 Y Y N N N N N N Y GI N 
27 Y Y N N N N N N Y GI N 
28 N Y Y N N N N N N PETECHIAE P 
S.NO MYALGIA ABD PAIN TEND DIST OLIGURIA PUFF FACE PEDAL EDEMA HEMATEMESIS MALENA BLEEDING HESS TEST 
29 Y N N N N N N N N N N 
30 Y Y N N Y N N Y Y GI N 
31 Y N N N N N N N Y GI P 
32 N N N N N N N Y N GI N 
33 N Y N N N N N N Y PETECHIAE N 
34 Y Y Y Y N N N N N N P 
35 Y N N N N N N N N N N 
36 N N N N N N N N N N N 
37 N Y N N N N N Y N GI N 
38 Y Y N N N N N N N EPISTAXIS N 
39 N Y Y N N N N N Y GI P 
40 Y Y N N N N N N Y GI N 
41 Y Y N Y N N N Y N GI P 
42 N Y N N N N N Y N GI N 
43 N N N N N N N N N N N 
44 Y Y N N N N N N N N N 
45 N Y Y N N N N N N N N 
46 Y Y N N N N N N Y GI N 
47 N N N N N N N N N N N 
48 Y Y N N N N N Y Y GI P 
49 Y N N Y N P N Y Y GI N 
50 N N N N N N N N N N N 
51 N N N Y N P P N Y GI P 
52 N Y Y Y N P P N Y GI N 
53 Y N N N N N N Y N GUM BLEED N 
54 Y N N N N N N N N N N 
55 N N N N N N N N N N N 
56 N Y N N N N N N N N N 
S.NO MYALGIA ABD PAIN TEND  DIST OLIGURIA PUFF FACE PEDAL EDEMA HEMATEMESIS MALENA BLEEDING HESS TEST 
57 Y N N N N P P N Y GI N 
58 N Y N Y N N N N Y PURPURA P 
59 Y N N N N N N N N N N 
60 N Y Y Y N N N N Y GI P 
61 N N N N Y N N N Y GI N 
62 Y N N N N N N N Y GI N 
63 N N N Y N N N Y Y IVSITE/SC ECHYMOSIS P 
64 N N N Y N P P Y Y GI N 
65 N N N Y N P P N Y GI P 
66 N N N N Y N N N N N N 
67 Y Y N N N N N Y Y GI P 
68 Y N N N N P N Y Y GI N 
69 N N N N N N N N N EPISTAXIS N 
70 Y Y Y Y N P P N Y GI N 
71 Y Y N N Y N N Y Y GI N 
72 N Y N N N N N N N N N 
73 N Y N N N N N N N N N 
74 Y Y N N Y N N Y Y GI N 
75 N Y N N N N N N N N N 
76 N Y Y Y N N N N Y GI N 
77 Y N N N N N N N Y GI N 
78 N N N N N N N N N N N 
79 Y Y N N N N N N N N N 
80 N Y Y Y N N N N N PURPURA N 
81 Y Y Y N N N N N N PETECHIAE N 
82 N Y N N N N N Y Y PURPURA N 
83 Y Y N Y N N N N N N P 
84 N N N Y Y P N N N N N 
S.NO MYALGIA ABD PAIN TEND DIST OLIGURIA PUFF FACE PEDAL EDEMA HEMATEMESIS MALENA BLEEDING HESS TEST 
85 N N N N N N N N Y GI N 
86 N N N N N P N N N PETECHIAE N 
87 N N N N Y N N N N N N 
88 N N N Y Y N N Y N GI N 
89 N N N N N P P N Y GI N 
90 Y Y N N N N N N N N N 
91 N N N N N P N N N N N 
92 N N N N N N N N N PETECHIAE N 
93 Y N N N N N N N N N N 
94 Y Y N N N N P N N N N 
95 N N N N N N N N Y PETECHIAE N 
96 Y N N N N N N N N PETECHIAE N 
97 Y N N N N N N N N PURPURA/ECCHYMOSIS N 
98 N N N N N N N N Y PURPURA/GUM BLEED N 
99 N Y N Y N P P Y Y PETECHIAE N 
100 Y Y N Y Y P N Y Y GI N 
101 Y Y N N N N N N N N N 
102 N N N Y N N N Y N GI N 
103 Y Y N N N N N N N N N 
104 N Y Y N N P N N Y GI N 
105 Y Y N N N N N N N GUM/PETECHIAE N 
106 N N N N N N N N N EPISTAXIS N 
107 Y Y N Y N N N N N N N 
108 Y Y N Y Y N N N Y GI N 
109 N Y Y N N N N Y Y GI N 
110 Y Y N Y Y P P Y Y GI N 
111 N N N N N P N Y N GI N 
112 Y N N N N N N Y N GI P 
S.NO RASH AVPU TACHYCARDIA TACHYPNEA PULSE PRES SHOCK SEIZURES INOTROPE VENTILATION TC HB ESR REF CNT 
1 ERYTH A N N 30 N N N N 4300 14 N 85000 
2 N A N N 30 N N N N 7900 11.9 I   
3 ERYTH IRRITABLE N N 20 N N N N 12400 8.1 N 110000 
4 N A Y N 30 N Y N N 15400 10.1 N   
5 FLUSH DROWSY N N 30 N N N N 5,400 11 N   
6 ERYTH A N N 25 N N N N 6200 11.9 N 2,66,000 
7 ERYTH LETHARGIC N N 25 N N N N 4100 12 I 2,50,000 
8 FLUSH A N N 40 N N N N 2700 13.7 N 99000 
9 N A N N 30 N N N N 6300 12.9 N 58000 
10 ERYTH LETHARGIC Y D 30 N N N N 12600 12.1 N 49000 
11 N LETHARGIC N D 25 N N N N 5100 13.2 N   
12 OLD HEALED LETHARGIC Y N 25 N N N N 2000 3.3 I   
13 FLUSH A N N 25 N N N N 3400 12.2 N   
14 ERYTH IRRITABLE N D 30 N N N N 13800 10.7 N 75000 
15 N A Y N 25 N N N N 2700 12.2 N   
16 ERYTH TOXIC N N 30 N N N N 14000 14.1 I   
17 ERYTH A N N 20 N N N N 4400 12 N 99000 
18 ERYTH A Y N 30 N N N N 5000 13.6 N 57000 
19 FLUSH A Y N 30 N N N N 3400 12.5 N   
20 N A Y N 20 N N N N 5200 14.9 N 450000 
21 ERYTH A Y N 30 N N N N 9300 14.5 I   
22 N A Y N 35 N N N N 4500 14.5 N   
23 ERYTH A N N 40 N N N N 3800 11.2 N 93000 
24 N LETHARGIC N N 30 N N N N 10400 12 N   
25 MACULOPAP A N N 25 N N N N 4400 9.5 N 47000 
26 N A N N 25 N N N N 10200 10.9 N 60000 
27 ERYTH A N N 30 N N N N 10900 9.7 N 73000 
28 ERYTH IRRITABLE N N 40 N N N N 7400 12.4 N 625000 
S.NO RASH AVPU TACHYCARDIA TACHYPNEA PULSE PRES SHOCK SEIZURES INOTROPE VENTILATION TC HB ESR REF CNT 
29 N A Y N 25 N N N N 3000 10.9 N 79000 
30 ERYTH IRRITABLE Y N 30 N N N N 1800 12.5 N   
31 N DROWSY N N 30 N N N N 9100 10.2 N   
32 N A N N 30 N N N N 18000 12.9 I 59000 
33 ERYTH TOXIC N N 30 N N N N 7800 15.2 N   
34 FLUSH LETHARGIC Y N 30 Y N N N 4100 13.1 N 72000 
35 N A N N 25 N N N N 2700 10.3 N   
36 N A N N 30 N N N N 2700 11.5 I 170000 
37 FLUSH A Y N 25 N N N N 6500 12.2 N   
38 FLUSH A N N 30 N N N N 10300 12.6 I 100000 
39 N LETHARGIC N N 20 N N N N 14100 10.5 N   
40 N SICK LOOK Y N 30 N N N N 5400 13.1 N 25000 
41 FLUSH A Y N 20 N N N N 5000 13.1 N   
42 ERYTH/FLUSH DROWSY Y D 30 Y N Y N 5700 12.8 N   
43 N A N N 20 N N N N 13400 11.6 I 52000 
44 N A Y N 30 N N N N 4000 13.4 N   
45 ERYTH A N N 40 N N N N 6000 14.5 N   
46 N A N N 30 N N N N 13000 11.3 N 90000 
47 ERYTH A N N 40 N N N N 4100 11.7 N   
48 FLUSH A N N 30 N N N N 3000 11.7 I 169000 
49 FLUSH IRRITABLE Y D 20 N N N N 18800 10.8 N 44000 
50 N A Y N 25 N N N N 6500 12.8 N   
51 ERYTH LETHARGIC Y D 30 Y N N N 12000 11.2 N 43000 
52 N A Y N 30 N N N N 11800 11.9 N 68000 
53 ERYTH A N N 20 N N N N 5800 12.2 I   
54 N A N N 30 N N N N 3400 13 N   
55 N A N N 30 N N N N 8300 12 I   
56 ERYTH A N N 40 N N N N 5800 11.2 N   
S.NO RASH AVPU TACHYCARDIA TACHYPNEA PULSE PRES SHOCK SEIZURES INOTROPE VENTILATION TC HB ESR REF CNT 
57 ERYTH A N N 20 N N N N 2600 7.9 N   
58 N LETHARGIC Y N 30 Y Y N N 10900 11.4 N 33000 
59 ERYTH A N N 20 N N N N 3500 12.8 I   
60 N DROWSY N N 30 N Y N N 6000 11.3 I 369000 
61 FLUSH TOXIC N N 30 N N N N 4600 11.6 I   
62 N A N N 25 N N N N 8400 14.5 N   
63 ERYTH DROWSY Y D 30 Y N N N 9800 5.7 N   
64 ERYTH STATUS Y D 30 Y Y Y Y 14100 8.8 N   
65 ERYTH IRRITABLE Y D 20 Y N Y Y 3800 11.2 N 38000 
66 ERYTH DROWSY Y N 30 Y N N N 9200 15.2 N 69000 
67 N DROWSY Y N 80 Y N N N 3500 11.5 N 254000 
68 N A N N 25 N N N N 12800 13 I 90000 
69 N DROWSY N N 30 N N N N 8000 12.6 N   
70 N A Y N 30 N N N N 11800 11.9 I 68000 
71 ERYTH A N N 25 N N N N 8200 13.2 I 78000 
72 N A Y N 40 N N N N 2800 10.3 I   
73 N A N N 30 N N N N 3100 12.7 N 110000 
74 N DROWSY Y N 30 Y N N N 4000 14 N   
75 ERYTH DROWSY N N 30 N N N N 18000 13.2 N   
76 N TOXIC Y N 30 N N N N 4100 12 N   
77 ERYTH A N N 25 N N N N 3500 12.9 I 73000 
78 ERYTH A Y N 30 N N N N 11100 10 N 368000 
79 N A N N 25 N N N N 4600 9.9 I   
80 ERYTH DROWSY Y D 30 Y Y N N 3900 12.3 I   
81 FLUSH A N N 25 N N N N 3800 12.8 I   
82 ERYTH IRRITABLE Y N 20 N N N N 11000 12.3 N 2,20,000 
83 DRY ?ADE TOXIC N N 30 N N N N 17700 8.8 I   
84 N A N D 30 N Y Y Y 5000 11.8 I 195000 
S.NO RASH AVPU TACHYCARDIA TACHYPNEA PULSE PRES SHOCK SEIZURES INOTROPE VENTILATION TC HB ESR REF CNT 
85 N IRRITABLE N N 25 N Y N N 5200 9.4 I   
86 ERYTH A N N 30 N N N N 8500 10.9 I   
87 N DROWSY Y D 20 Y Y Y Y 3900 8.7 I   
88 N DROWSY Y D 25 Y Y Y Y 11000 9 N   
89 ERYTH LETHARGIC N N 36 N N N N 17200 7.3 I 41000 
90 N LETHARGIC N N 30 N N N N 3200 12.4 N 72000 
91 N A Y N 20 N N N N 5100 13.4 I   
92 ERYTH LETHARGIC N N 30 N N N N 1100 6.6 I   
93 N A N N 30 N N N N 35300 1.8 I   
94 N A Y N 30 N N N N 25600 2.7 I   
95 N A N N 30 N N N N 3300 4.5 N   
96 N A N N 25 N N N N 32800 5.7 I   
97 ERYTH A N N 25 N N N N 11600 9.6 N 16000 
98 N A N N 25 N N N N 5000 9.2 I   
99 N DROWSY Y D 30 Y N Y Y 5600 8.3 I   
100 N DROWSY Y D 30 N N N N 12000 8.7 N   
101 ERYTH A N N 30 N N N N 7300 12.5 N   
102 ERYTH LETHARGIC Y D 25 Y N Y Y 3000 5 I   
103 N A N N 30 N N N N 3800 8.1 N   
104 ERYTH DROWSY Y N 20 N N N N 15400 9.1 I   
105 N A Y N 30 N N N N 2900 7 N   
106 N A N N 20 N N N N 6700 11.8 N   
107 N A N N 30 N N N N 2400 5.7 N   
108 ERYTH TOXIC Y D 20 Y N N N 3300 15.9 N   
109 N IRRITABLE Y D 34 N Y N N 15,700 15.9 I   
110 FLUSH P Y N 20 N Y N N 22700 9.5 I   
111 N P Y D 20 Y Y N N 22500 8.7 N   
112 N U Y D 50 Y Y N N 33300 12.4 I   
S.NO R 1 PCV R2 PCV2 R3 PCV3 R4 R5 UREA CREAT SUGAR LIVER ENZ BILIRUBIN IGM IGG NSI WIDAL 
1 80,000 42 72000 42.6 120000 43.5 200000   18 0.8 78 N N P P P N 
2 74000 37.4 90000 36 120000 36     29 0.8 60 N N P N N N 
3 58000 30.2 1,10,000 31.8 175000 27.9     48 0.8 60 N N P P N N 
4 47000 31.8 1,29,000           68 1 21 I 200 I P P N N 
5 1,49,000 34.4 25,000 37 23,000 40 15,000 1,29,000 32 1 54 N N P P N N 
6 2,02,000 36.7 99,000 37.3 150000 36     30 0.9 67 N N N N P N 
7 1,80,000 38.7 39,000 37 90000 38     55 1.5 148 N N P N N N 
8 96000 43.2 1,00,000 36 2,72,000 35     25 0.9 38 N N N P N N 
9 79000 40.8 211,000 42         16 0.6 139 N N P P N N 
10 47000 39.1 72,000 39 142000 37     18 0.8 73 N N P P N N 
11 25000 41.7 37000 34.5 72000 34 145000   22 0.7 75 N N P N P N 
12 29000 10.1 41000 17.4 94000 18 102000   15 0.7 104 N N P N N N 
13 119,000 39.3 79000 39.4 120000 38     20 0.8 87 N N N P N N 
14 79000 34.1 135000 34.5         25 0.8 60 N N P N P N 
15 84000 36.7 94000 37.9 145000 37.3     18 0.8 65 I 300 N P P N N 
16 27000 40 40000 41 67000 40 122000   41 0.9 76 I 200 N P P N N 
17 92000 38.6 144000 36         19 0.7 80 N N P P P N 
18 46000 39.9 54000 40.2 76000 40 137000   19 0.9 74 I 3000 N P P N N 
19 60000 37 15000 39 82000 34.1 150000   24 36 1.4 N N P P  N  N 
20 68000 45.5 90000 38 200000 36     19 0.9 65 I 200 N P P P N 
21 46000 33 25000 35 58000 37 72000 175000 42 1 60 I 200 N P P N N 
22 21000 46.2 43000 37 79000 36.8 120000   46 1.5 107 N N P P N N 
23 87000 38.9 131000 35 225000 36.3     18 0.7 82 I 300 N P P N N 
24 92000 37.7 100000 36 250000 37     23 0.8 89 N N P N P N 
25 43000 37.1 145000 30.1 140000 32.6     18 0.8 85 N N P P N N 
26 62000 32.8 97000 33 167000 34     35 1.1 35 N N P N N N 
27 90000 33.1 125000 34         18 0.8 8 N N P N P N 
28 46000 54.2 25000 53.3 21000 45.5 33000 102000 37 1.2 92 I  519 N P N N N 
S.NO R 1 PCV R2 PCV2 R3 PCV3 R4 R5 UREA CREAT SUGAR LIVER ENZ BILIRUBIN IGM IGG NSI WIDAL 
29 84000 35 120000 36         29 0.8 95 N N N N P N 
30 103000 38.2 82000 38.9 127800 37     18 0.8 62 N N P N N N 
31 78000 37.5 141000 36         33 1.2 72 N N P P P N 
32 55000 43 238000 40         21 0.8   N N P P N N 
33 20000 47.4 31000 45 54000 43 79000 135000 45 1.3 57 N N N N P N 
34 52000 49.6 26000 41 36000 41.2 98000 123000 26 1 50 N N P N N N 
35 79000 34.6 98000 33.9 129000 32     26 1 76 N N P N P N 
36 47000 37.8 74000 36.7 147000 35     45 0.8 118 N N N N P N 
37 33000 39.4 118000 33.5         45 1.3 75 N N P N P N 
38 23000 39.4 26000 39 100000 34 123000   45 1.3 62 N N P N N N 
39 18000 47.7 24000 39.4 74000 32 190500   34 1.1   I 1457 N P P P N 
40 28000 55.9 19000 46.6 13000 39.2 47000 103000 49 1 109 I  518 N P P N N 
41 45000 39.9 55000 38 76000 37.4 112000   41 1.3 113 I  488 N P P P N 
42 42000 53.8 42000 52.5 12000 41.4 16000 18000 29 0.8 82 N N P N N N 
43 30000 38.2 47000 38.1 94000 37 123000   32 1.1 90 N N P P N N 
44 93000 42.2 118000 40         26 0.8 105 N N N N P N 
45 64000 46.3 57000 39.3 79000 38 145000   53 1.5 84 I 277 I N P N N 
46 80000 33.9 227000 32         16 0.6   I 716 N P N P N 
47 75000 36.2 123000 32.8         31 1.2 90 N N P N N N 
48 63000 36.6 20000 41.1 72000 40 134000   40 1   N N P N P N 
49 44000 36 49000 37 76000 35.2 133000   23 0.8 65 N N P N N N 
50 62000 34.4 86000 35 120000 33     26 1.1 106 N N N P N N 
51 43000 35.1 11000 29.6 16000 30 50000 72000 26 1.2   N N P N N N 
52 58000 36.7 97000 37.3 167000 36     34 1.1 101 I 400 N P N P N 
53 65000 38 87000 37 112000 36.8     24 1 62 N N P P N N 
54 72000 39 98000 38 127000 35.7     31 1.2 94 N N N P N N 
55 76000 37.3 114000           24 0.8 46 N N P N P N 
56 64000 36.5 92000 35.5 158000 34     21 0.8 89 N N P P N N 
S.NO R 1 PCV R2 PCV2 R3 PCV3 R4 R5 UREA CREAT SUGAR LIVER ENZ BILIRUBIN IGM IGG NSI WIDAL 
57 67000 25.5 125000 27.4         26 0.8 109 N N P N N N 
58 31000 34.7 36000 33 63000 32 67000 176000 22 1 62 N N P N N N 
59 42000 40.2 74000 41 89000 38 156000   26 0.8 117 I 208 N P N N N 
60 104000 46.2 53000 34.1 76000 35.4 123000 150000 49 1.2 68 N N P N N N 
61 71000 35.7 86000 34 98000 33 125000   20 0.8 65 N N N P N P 
62 91000 44.4 102,000 36         32 0.8   N N P P P N 
63 37000 17.3 35000 17 30000 18 23000 7000 44 0.9   N N P N N N 
64 19000 30 39000 34.3 20000 32 18000 16000 42 1.3 22 N N P N N N 
65 30000 38.1 15,000 41.8 13000 32.1 11000 10000 30 1 90 N N P P N N 
66 45000 44 29000 45.3 33000 39.6 78000 124000 19 0.9 60 N N P P P N 
67 108000 39.8 59000 36.7 35000 44.1 20000 130000 49 1.2 90 N N P N N N 
68 76000 39 74,000 30 350000 31     56 1 65 N I N N N P 
69 2,79,000 40.5 60,000 42 74000 40 117000 200000 18 0.8 181 N N N N N P 
70 58000 36.7 97000 37.3 178000 36     34 1.1 101 I 400 N N N N P 
71 68000 39.4 86000 38 145000 34     28 0.8 78 I  400 N N N N N 
72 42000 39.1 44000 31.6 75000 32 88000 156000 23 0.8 68 I  650 N N N N P 
73 67000 44.8 76000 43 110000 40 156000   24 0.8 79 I  650 N N N N P 
74 77000 4.3 149000 36         25 0.7 84 N N N N N P 
75 43000 41.3 37000 34.5 48000 37.6 74000 122200 39 1.2 104 N N N N N P 
76 129000 37.5 79000 40.5 87000 40 136000   17 0.7 63 I 200 N N N N P 
77 37000 41.4 39000 39.7 54000 38 131000   17 0.7 81 N N N N N P 
78 90000 31 96000 32 115000 32 178000   22 1 84 N N N N N P 
79 84000 32 123000 34         24 0.9 84 N N N N N P 
80 24000 49.7 36000 37.4 38000 35.6 50000 97000 34 1.1 58 N N N N N P 
81 28000 40.2 57000 39 72000 38 112000 126000 32 1   I 202 I P P N P 
82 49000 38.3 44,000 37.6 1,39,000 36     31 1.1 84 I 250 N P P N P 
83 23000 28 58,000 28.7 76000 29 120000   21 0.8 80 N N P P N P 
84 44000 36.3 61000 41.4 85000 37.7 125000   15 0.7 60 N N N N N N 
S.NO R 1 PCV R2 PCV2 R3 PCV3 R4 R5 UREA CREAT SUGAR LIVER ENZ BILIRUBIN IGM IGG NSI WIDAL 
85 75000 31.5 79000 30 112000 29 200000   15 0.7 83 N N N N N N 
86 91000 32 94000 31 114800 28 180000   28 0.9   N N N N N N 
87 40000 26 43000 25 13000 24 11000 10000 43 0.8 60 N N N N N N 
88 67000 27 72000 28 45000 25.6 40000 34000 60 1.2 45 N N N N N N 
89 53000 21.6 1,09,000 21.9         29 0.9 99 N N N N N N 
90 88000 37.8 130000 36.8 200000 34     34 1.1 128 N N N N N N 
91 35000 44 26000 43.4 26000 38.7 74000 132000 25 0.8 115 I 200 N N N N N 
92 83000 19.4 78000 19.6         37 0.8   N N N N N N 
93 9000 5.2 9700 5.6         34 0.9   N N N N N N 
94 45000 11.8 84000 11.5         20 0.9 81 N N N N N N 
95 30000 15.6 33000 14         74 1.3 104 N N N N N N 
96 16000 14.8 17000 15         24 1   N N N N N N 
97 13000 45.5 16000 33.4 46000       33 1 76 N N N N N N 
98 9000 29 12000 28 15000 27 34000 50000 30 1 75 N N N N N N 
99 70000 28 34000 26 32000 20 16000 12000 58 1.4 89 I  560 N N N N N 
100 18000 26 20000 27 34000 28 68000 120000 63 1.4 76 I 300 I N N N N 
101 90000 38 148000 38.4         29 0.6   I 1106 I N N N N 
102 19000 15 12000 14.7 11000 14.4 7000 8700 60 2 68 I  483 I N N N N 
103 79000 24 100000 23.6 120000 24     41 0.9 87 N N N N N N 
104 13000 44.2 11000 30.1 56000 28.8 62000 112000 24 1 62 I 2500 I N N N N 
105 6000 29.2 12000 28 20000 29.6 22000 24000 22 0.8 62 N N N N N N 
106 87000 35.1 112000 35.1         27 0.8 118 N N N N N N 
107 24000 20 20000 19.8 22000 19.6     24 0.9   N I N N N N 
108 25000 49.2 27000 47 32000 42 65000 100000 30 1 114 I 2500 I N N N N 
109 16,000 50.7 11,000 46.7 17,000 45.8 49,000 96,000 33 1 44 I 800 I N N N N 
110 33000 37.4 40000 29.3 1,79,000 31.5     25 1 68 I 1861 N N N N N 
111 35000 43 119000           117 8 123 I 350 I N N N N 
112 78000 39 77000 36.5 99000 34.5 112000   49 1.2 51 I 395 N N N N N 
S.NO USGGB  PE ASCITES HM SPM CXR TRANS BLD C/S PS MP MARROW DIAGNOSIS OUTC HEARD  AWARE TRANS 
1 N N N N N N N NG N N NA DF DIS Y Y Y 
2 Y Y Y N N N N NG MCHC N NA DHF DIS N N N 
3 N Y N N N PE N NG MCHC N NA DHF DIS Y N Y 
4 Y Y N Y N N N NG NCNC N NA DHF DIS Y N N 
5 N N N N N N 10  NG MCHC N NA DF DIS Y Y N 
6 N N N N N N N NG N N NA DF DIS N N N 
7 N N N N N N N NG N N NA DF DIS N N N 
8 N N N N N N N NG N N NA DF DIS Y Y N 
9 N N N Y Y N N NG N N NA DF DIS N N N 
10 N N N Y Y BP N NG N N NA DF DIS N N N 
11 N N N N N N N NG MCHC N NA DF DIS N N N 
12 N N N N N N 25  NG PANC N N DF DIS Y N Y 
13 N N N N N N N NG N N NA DF DIS N N N 
14 N N N N N N N NG NCNC N NA DF DIS N N N 
15 Y N N N N N N NG N N NA DHF DIS Y Y N 
16 Y Y Y Y Y N N NG N N NA DHF DIS N N N 
17 N N N Y Y N N NG N N NA DF DIS Y N Y 
18 Y N N Y Y N N NG N N NA DHF DIS N N N 
19 Y Y Y N N PE N NG N N NA DHF DIS Y N Y 
20 N N N Y Y N N NG N N NA DF DIS Y N Y 
21 N Y N N N N N NG N N NA DHF DIS N N N 
22 N Y N Y N N N NG N N NA DHF DIS Y N Y 
23 Y N N Y Y N N NG N N NA DHF DIS N N N 
24 N N N Y Y N N NG N N NA DF DIS Y Y Y 
25 N N N Y N N N NG MCHC N NA DF DIS Y N Y 
26 N N N Y Y N N NG MCHC N NA DF DIS N N N 
27 N N N Y N N N NG MCHC N NA DF DIS Y N Y 
28 N Y Y N N PE/BP N NG N N NA DHF DIS N N N 
S.NO USGGB  PE ASCITES HM SPM CXR TRANS BLD C/S PS MP MARROW DIAGNOSIS OUTC HEARD  AWARE TRANS 
29 N N N N N N N NG NCNC N NA DF DIS Y N Y 
30 N N N Y N N N NG N N NA DF DIS Y Y Y 
31 Y Y N N N N N NG MCHC N NA DHF DIS Y N Y 
32 N N N N N N N NG N N NA DF DIS N N N 
33 N N N Y N N 30  NG N N NA DF DIS N N N 
34 N Y Y N N N N NG N N NA DSS DIS N N N 
35 N N N N N N N NG NCNC N NA DF DIS N N N 
36 N N N N N N N NG N N NA DF DIS Y Y N 
37 N Y N N N N N NG N N NA DHF DIS N N N 
38 N N N N N N N NG N N NA DF DIS N N N 
39 N Y Y N N N N NG NCNC N NA DHF DIS N N N 
40 Y Y Y N N PE N NG N N NA DHF DIS Y Y Y 
41 N N Y N N N N NG N N NA DHF DIS N N N 
42 N N N N N N 120  NG N N NA DSS DEATH N N N 
43 N N N N N N N NG N N NA DF DIS Y N Y 
44 N N N N N N N NG N N NA DF DIS N N N 
45 N N N N N N N NG N N NA DF DIS N N N 
46 N N N Y N N N NG N N NA DF DIS Y N Y 
47 N N N N Y N N NG N N NA DF DIS N N N 
48 Y Y N Y N N N NG N N NA DHF DIS Y Y N 
49 N N N N N N 30  NG MCHC N NA DF DIS Y N Y 
50 N N N N N N N NG N N NA DF DIS N N N 
51 Y Y N N N N 40  NG MCHC N NA DSS DIS N N N 
52 Y Y N Y Y PE N NG N N NA DHF DIS Y Y Y 
53 N N N N N N N NG N N NA DF DIS N N N 
54 N N N N N N N NG N N NA DF DIS N N N 
55 N N N N N N N NG N N NA DF DIS Y N Y 
56 N N N N N N N NG N N NA DF DIS N N N 
S.NO USGGB   PE ASCITES HM SPM CXR TRANS BLD C/S PS MP MARROW DIAGNOSIS OUTC HEARD  AWARE TRANS 
57 N Y Y Y Y N N NG MCHC N NA DHF DIS N N N 
58 Y Y Y N N N 15  NG N N NA DSS DIS Y Y N 
59 N N N N N N N NG N N NA DF DIS N N N 
60 N Y Y Y N N N NG N N NA DHF/CNS DIS Y N N 
61 N N N Y N N N NG N N NA E/D DIS N N N 
62 N N N N N N N NG N N NA DHF DIS N N N 
63 N N N Y N N 90  NG MCHC N NA DSS DEATH N N N 
64 N N N Y N N 30 NG MCHC N NA DSS/ICH DEATH Y N N 
65 Y Y Y N N PE/BP 45 NG N N NA DSS DEATH N N N 
66 N Y N Y N N N NG N N NA DSS DIS N N N 
67 Y N N N N N 110 NG N N NA DSS DIS Y Y Y 
68 Y Y N Y N N N NG N N NA ENTERIC DIS N N N 
69 Y N N Y N N N NG N N NA ENTERIC DIS Y Y Y 
70 Y Y N Y Y PE N NG N N NA ENTERIC DIS N N N 
71 Y Y Y Y Y N N NG N N NA ENTERIC DIS N N N 
72 N N N Y N N N NG NCNC N NA ENTERIC DIS Y N N 
73 Y N Y Y N RLE N NG N N NA ENTERIC DIS N N N 
74 Y N N Y N N N NG MCHC N NA ENTERIC DIS N N N 
75 N N N Y Y N 30  NG N N NA ENTERIC DIS N N N 
76 Y Y Y N N N N CONS N N NA ENTERIC DIS N N N 
77 Y N N N N N N NG N N NA ENTERIC DIS N N N 
78 N N N N N N N NG MCHC N NA ENTERIC DIS N N N 
79 N N N Y Y N N NG MCHC N NA ENTERIC DIS Y Y Y 
80 N N N Y N N N NG N N NA ENTERIC DIS N N N 
81 N N N N N N N NG N N NA E/D DIS N N N 
82 Y N N Y N N N NG NCNC N NA E/D DIS N N N 
83 N N Y Y Y N N NG NCNC N NA E/D/UTI DIS N N N 
84 Y N N N N PE N KLEBS N N NA SEPTICEMIA DIS N N N 
S.NO USGGB  PE ASCITES HM SPM CXR TRANS BLD C/S PS MP MARROW DIAGNOSIS OUTC HEARD  AWARE TRANS 
85 Y Y N Y Y BP N CONS MCHC N NA SEPTICEMIA DIS Y N N 
86 N Y N N N N N PSEUDO MCHC N NA SEPTICEMIA DIS N N N 
87 N N N N N BP N PSEUDO NCNC N NA MENINGITIS DEATH Y N Y 
88 N N N N N BP 15  CONS MCHC N NA SEP SHOCK DEATH N N N 
89 Y Y N Y Y N N NG MCHC P NA MALARIA DIS Y N Y 
90 N N N N N N N NG N P NA MALARIA DIS N N N 
91 N Y Y Y N N N NG N P NA MALARIA DIS N N N 
92 Y N Y N N N 20 NG BLASTS N ALL ALL REF N N N 
93 N N N N Y N N NG BLASTS N ALL ALL REF Y N N 
94 N N N Y Y N 30 NG BLASTS N ALL ALL REF N N N 
95 N N N N Y N N NG BLASTS N ALL ALL REF N N N 
96 N N N N N N N NG          BLASTS N ALL ALL REF Y Y Y 
97 N N N N Y N N NG  RED PLTS N MGK ITP DIS Y N Y 
98 N N N N N N N NG  RED  PLTS N MGK ITP DIS N N N 
99 N N N N N N N NG N N NA SNAKE BITE DEATH Y Y Y 
100 N N N N N N 55  NG N N NA SNAKE BITE DIS N N N 
101 N N N Y N N N NG N N NA HEPATITIS DIS N N N 
102 N N N N Y BP 30  NG HPH N HPH HPH DEATH N N N 
103 N N N N N BP N NG MCHC N NA HIV/OPP I DIS Y Y N 
104 Y N N Y Y N 10 NG MCHC/ATYP LYM N NA LEPTO DIS N N N 
105 N N N N N N N NG RED RBC/PLTS N APLASIA A.ANEMIA REF N N N 
106 N N N N N N N NG MCHC/ATYP LYM N N LYMPHOMA REF Y Y N 
107 N N N Y Y N N NG NUC RBC/HLYSIS N PAN THAL /HS DIS N N N 
108 Y N Y Y Y N N NG N N NA UND DIS N N N 
109 N N N N N N 105 NG N N N UND DIS Y Y Y 
110 N N N Y N N 35 NG MCHC N N UND DIS N N N 
111 Y Y N Y Y N N NG MCHC N NA UND DIS Y Y Y 
112 N N N N N N N NG N N NA UND DIS N N N 
KEY TO MASTER CHART 
S.NO   -         SERIAL NUMBER                                                                                     
IP NO              -         INPATIENT NUMBER 
WT   -        WEIGHT IN KG 
WT FOR AGE -   IAP GRADING OF MALNUTRITION 
N   -      NORMAL 
PRE HOSP  -    PRE HOSPITAL TREATMENT RECEIVED 
PVT   - PRIVATE HOSPITAL 
GH   - GOVERNMNENT DISTRICT HQ HOSPITAL 
PHC   - PRIMARY HEALTH CENTRE 
ADEQ              - ADEQUACY OF PRE HOSPITAL TREATMENT 
A   - ADEQUATE 
I   - INADEQUATE 
NA   -       NOT APPLICABLE 
STAY              -    HOSPITAL STAY IN DAYS 
ADM FEVER             -     NO. OF FEBRILE DAYS ON ADMISSION 
TOTAL  FEVER - DURATION FOR WHICH FEVER LASTED 
Y   -    YES 
N   -      NO 
TEND              -     ABDOMINAL TENDERNESS 
DIST   -     ABDOMINAL DISTENSION 
PUFF FACE             -    FACIAL PUFFINESS 
GI   -  GASTROINTESTINAL 
P   -   POSITIVE 
ERYTH  -     ERYTHEMATOUS RASH 
ADE   -   ADVERSE DRUG ERUPTION 
AVPU              -    ALERT/VERBAL/PAIN RESPONSIVE/UNRESPONSIVE 
PULSE PRES             -    PULSE PRESSURE IN mm Hg 
TC   -      TOTAL WBC COUNT 
HB   -   HEMOGLOBIN IN GM% 
I   - INCREASED 
REF CNT  -     REFERRAL PLATELET COUNT 
R1,2,3,4  -  REPEAT PLATELET COUNTS 
PCV   -      HEMATOCRIT IN % 
CREAT  -     CREATININE 
USG GB  -   ULTRASOUND PERICHOLECYSTIC EDEMA 
PE   -       PLEURAL EFFUSION 
HM   -    ULTRASOUND HEPATOMEGALY 
SPM   -    ULTRASOUND SPLENOMEGALY 
BP   -    BRONCHOPNEUMONIA 
RLE   -     RIGHT LAMELLAR EFFUSION 
CXR   -      CHEST X RAY 
TRANS  -      TRANSFUSED BLOOD PRODUCT VOLUME IN ML/KG/PATIENT 
BLD C/S  -    BLOOD CULTURE AND SENSITIVITY 
CONS              -       COAGULASE NEGATIVE STAPHYLOCOCCUS AUREUS 
PSEUDO  -   PSEUDOMONAS 
KLEBS  -    KLEBSIELLA 
PS   -     PERIPHERAL SMEAR 
MC   -     MICROCYTIC 
HC   -      HYPOCHROMIC 
NC   -   NORMOCHROMIC/CYTIC 
PANC               -        PANCYTOPENIA 
BLASTS  -    LYMPHOBLASTS WITH PROMINENT NUCLEOLI 
RED PLTS  -  SEVERE REDUCTION IN THE PLATELET POPULATION 
HPH   -     HEMOPHAGOCYTIC HISTIOCYTOSIS 
NUC RBC  -  NUCLEATED RBC SUGG OF HEMOLYSIS 
ATYP LYM  - ATYPICAL LYMPHOCYTES 
MP   -    PER SMEAR FOR MALARIAL PARASITE 
MGK   -      MEGAKARYOCYTE PREDOMINANCE IN THE BONE MARROW 
APLASIA  -   RED CELL APLASIA WITH DECREASE IN PLATELETS 
DF   -     DENGUE FEVER 
DHF   - DENGUE HEMORRHAGIC FEVER 
DSS   -    DENGUE SHOCK SYNDROME 
ICH   -      INTRACRANIAL HEMORRHAGE 
E/D   -      ENTERIC/DENGUE CO INFECTION 
ALL   -     ACUTE LYMPHOBLASTIC LEUKEMIA 
OPP I   -    OPPORTUNISTIC INFECTION 
LEPTO  -   LEPTOSPIROSIS 
A ANEMIA  - APLASTIC ANEMIA 
THAL/HS  -   THALASSEMIA MAJOR/HYPERSPLENISM 
UND   -        UNDIAGNOSED 
DIS   -    DISCHARGED 
REF   -     REFERRED 
OUTC              -      OUTCOME 
HEARD  -      HEARD THE WORD DENGUE 
AWARE  -     AWARE OF SIGNS AND SYMPTOMS OF DISEASE 
TRANS  -       AWARE OF TRANSMISSION THRO MOSQUITOES 
 
